Zhongchao (ZCMD) 20-F 11 May 23 2022 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Document Information Line Items
Entity Registrant Name	Zhongchao Inc.
Trading Symbol	ZCMD
Document Type	20-F
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001785566
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-39229
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	Nanxi Creative Center
Entity Address, Address Line Two	Suite 218
Entity Address, Address Line Three	841 Yan’an Middle Road
Entity Address, City or Town	Jing’An District
Entity Address, Country	CN
Entity Address, Postal Zip Code	200040
Title of 12(b) Security	Class A Ordinary shares, par value $0.0001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	U.S. GAAP
Auditor Firm ID	5395
Auditor Name	Marcum Asia CPAs LLP
Auditor Location	New York, NY
Business Contact
Document Information Line Items
Entity Address, Address Line One	Nanxi Creative Center
Entity Address, Address Line Two	Suite 218
Entity Address, Address Line Three	841 Yan’an Middle Road
Entity Address, City or Town	Jing’An District
Entity Address, Country	CN
Entity Address, Postal Zip Code	200040
Contact Personnel Name	Weiguang Yang
City Area Code	021
Local Phone Number	32205987
Class A Ordinary Share
Document Information Line Items
Entity Common Stock, Shares Outstanding	20,531,423
Class B Ordinary Share
Document Information Line Items
Entity Common Stock, Shares Outstanding	5,497,715

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 11,520,453	$ 13,914,982
Short-term investments	518,416	296,158
Accounts receivable	6,772,988	9,218,883
Inventories	189,106
Prepayments	1,027,989	394,971
Prepayments – related party	115,989
Loans receivable	1,840,000	2,660,668
Due from a related party	226,179	392,305
Other current assets	493,040	375,709
Total Current Assets	22,704,160	27,253,676
Investment in equity method investees	1,179,300	1,993,285
Investment in an equity security	84,606	150,000
Goodwill	5,767,504
Property and equipment, net	3,890,947	3,923,086
Deposit for property	239,481	181,233
Prepayments for lease of land	304,787	353,347
Intangible assets, net	912,054	30,259
Right of use assets	1,666,777	205,824
Deferred tax assets	1,864,729	2,176,710
Total Assets	38,614,345	36,267,420
Current Liabilities
Accounts payable	140,834	38,933
Advances from customers	395,263	7,432
Income tax payable	2,292,765	2,478,273
Operating lease liabilities, current portion	480,633	88,968
Accrued expenses and other liabilities	855,540	974,801
Total Current Liabilities	4,165,035	3,588,407
Operating lease liabilities, noncurrent portion	1,221,845	112,591
Deferred tax liabilities	208,200
Total Liabilities	5,595,080	3,700,998
Commitments and Contingencies
Equity
Class A Ordinary Share (par value $0.0001 per share, 450,000,000 shares authorized; 20,531,423 and 19,453,423 shares issued and outstanding at December 31, 2022 and 2021, respectively)	2,054	1,946
Class B Ordinary Share (par value $0.0001 per share, 50,000,000 shares authorized; 5,497,715 and 5,497,715 shares issued and outstanding at December 31, 2022 and 2021, respectively)	550	550
Additional paid-in capital	24,998,388	22,986,975
Statutory reserve	1,315,017	1,199,054
Retained earnings	4,124,037	7,180,891
Accumulated other comprehensive (loss) income	(511,824)	1,197,006
Total Zhongchao Inc. Shareholders’ Equity	29,928,222	32,566,422
Non-controlling interests	3,091,043
Total Equity	33,019,265	32,566,422
Total Liabilities and Equity	$ 38,614,345	$ 36,267,420

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Class A Ordinary Share
Ordinary Share par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary Share authorized	450,000,000	450,000,000
Ordinary Share issued	20,531,423	19,453,423
Ordinary Share outstanding	20,531,423	19,453,423
Class B Ordinary Share
Ordinary Share par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary Share authorized	50,000,000	50,000,000
Ordinary Share issued	5,497,715	5,497,715
Ordinary Share outstanding	5,497,715	5,497,715

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues	$ 14,151,516	$ 16,296,770	$ 17,989,788
Cost of revenues	(7,794,852)	(6,857,944)	(6,117,640)
Gross Profit	6,356,664	9,438,826	11,872,148
Operating Expenses
Selling and marketing expenses	(2,099,968)	(3,137,316)	(3,441,941)
General and administrative expenses	(6,799,634)	(5,863,373)	(3,124,301)
Research and development expenses	(411,524)	(758,878)	(816,553)
Total Operating Expenses	(9,311,126)	(9,759,567)	(7,382,795)
(Loss) Income from Operations	(2,954,462)	(320,741)	4,489,353
Interest income, net	142,014	175,987	146,965
Other income, net	262,442	34,001	305,566
(Loss) Income Before Income Taxes	(2,550,006)	(110,753)	4,941,884
Income tax (expenses) benefits	(272,313)	349,418	(484,787)
Net (Loss) Income	(2,822,319)	238,665	4,457,097
Net (income) loss attributable to noncontrolling interests	(118,572)		1,283
Net (Loss) Income Attributable to Zhongchao Inc.’s shareholders	(2,940,891)	238,665	4,458,380
Other Comprehensive (Loss) Income
Foreign currency translation adjustment	(1,715,262)	281,793	1,259,984
Comprehensive (Loss) Income	(4,537,581)	520,458	5,717,081
Total comprehensive (income) loss attributable to noncontrolling interests	(112,139)		1,283
Total Comprehensive (Loss) Income Attributable to Zhongchao Inc.’s Shareholders	$ (4,649,722)	$ 520,458	$ 5,718,364
Weighted Average Number of Ordinary Share Outstanding
Basic (in Shares)	25,997,757	24,938,513	24,425,637
(Loss) Earnings per Share
Basic (in Dollars per share)	$ (0.113)	$ 0.01	$ 0.183

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive (Loss) Income (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Diluted	25,997,757	24,938,513	24,425,637
Diluted	$ (0.113)	$ 0.010	$ 0.183

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($)	Class A Ordinary Share	Class B Ordinary Share	Additional paid-in capital	Statutory Reserve	Retained earning	Accumulated other comprehensive (loss) income	Non-controlling interest	Total
Balance at Dec. 31, 2019	$ 1,610	$ 550	$ 12,044,855	$ 415,813	$ 3,267,087	$ (344,771)	$ (46,617)	$ 15,338,527
Balance (in Shares) at Dec. 31, 2019	16,102,420	5,497,715
Share-based compensation expenses			168,350					168,350
Issuance of Class A Ordinary Shares pursuant to initial public offering, net of issuance costs	$ 332		10,609,851					10,610,183
Issuance of Class A Ordinary Shares pursuant to initial public offering, net of issuance costs (in Shares)	3,315,003
Issuance of restricted Class A Ordinary Shares to non-executive directors	$ 2		(2)
Issuance of restricted Class A Ordinary Shares to non-executive directors (in Shares)	18,000
Net (loss) income					4,458,380		(1,283)	4,457,097
Appropriation of statutory reserve				385,689	(385,689)
Buy out of a non-controlling interests			(47,900)				47,900
Foreign currency translation adjustments						1,259,984		1,259,984
Balance at Dec. 31, 2020	$ 1,944	$ 550	22,775,154	801,502	7,339,778	915,213		31,834,141
Balance (in Shares) at Dec. 31, 2020	19,435,423	5,497,715
Share-based compensation expenses			211,823					211,823
Issuance of restricted Class A Ordinary Shares to non-executive directors	$ 2		(2)
Issuance of restricted Class A Ordinary Shares to non-executive directors (in Shares)	18,000
Net (loss) income					238,665			238,665
Appropriation of statutory reserve				397,552	(397,552)
Foreign currency translation adjustments						281,793		281,793
Balance at Dec. 31, 2021	$ 1,946	$ 550	22,986,975	1,199,054	7,180,891	1,197,006		32,566,422
Balance (in Shares) at Dec. 31, 2021	19,453,423	5,497,715
Issuance of Class A Ordinary Shares in connection with public offering	$ 106		1,850,638					1,850,744
Issuance of Class A Ordinary Shares in connection with public offering (in Shares)	1,060,000
Share-based compensation expenses	$ 2		160,775					160,777
Share-based compensation expenses (in Shares)	18,000
Acquisition of subsidiaries							2,978,903	2,978,903
Net (loss) income					(2,940,891)		118,572	(2,822,319)
Appropriation of statutory reserve				115,963	(115,963)
Foreign currency translation adjustments						(1,708,830)	(6,432)	(1,715,262)
Balance at Dec. 31, 2022	$ 2,054	$ 550	$ 24,998,388	$ 1,315,017	$ 4,124,037	$ (511,824)	$ 3,091,043	$ 33,019,265
Balance (in Shares) at Dec. 31, 2022	20,531,423	5,497,715

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net (loss) income	$ (2,822,319)	$ 238,665	$ 4,457,097
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Provision of doubtful accounts receivable	753,447	1,449,827	336,367
Depreciation and amortization expenses	383,286	341,608	202,325
Gain from disposal of property and equipment	(96,921)
Amortization of right of use assets	347,025	361,369	222,353
Share-based compensation expenses	160,777	211,823	168,350
Deferred tax expenses (benefits)	134,125	(1,346,616)	(58,424)
Changes in fair value of short-term investments	240,489	58,403	10,331
Downward adjustments in investments in an equity security	65,394
Equity investment loss	80	13,758	25,622
Changes in operating assets and liabilities:
Accounts receivable	1,076,292	(104,230)	(5,486,914)
Prepayments	(659,496)	171,144	(197,402)
Prepayments – related party	(118,888)
Inventories	(193,833)
Other current assets	66,148	1,302,009	(1,143,200)
Accounts payable	103,825	(375,144)	260,350
Advances from customers	369,249	496	6,398
Income tax payable	3,557	905,733	535,981
Accrued expenses and other liabilities	(167,585)	(4,430)	179,738
Lease liabilities	(306,392)	(362,567)	(230,819)
Deferred government grants			(325,992)
Net Cash (Used in) Provided by Operating Activities	(661,740)	2,861,848	(1,037,839)
Cash Flows from Investing Activities:
Purchases of property and equipment	(1,615,905)	(1,799,860)	(160,602)
Proceeds from disposal of property and equipment	1,112,440
Payments of deposits for property purchase	(245,467)		(688,267)
Investments in short-term investments	(996,638)		(2,043,259)
Release from short-term investments	533,891	1,678,367
Investment in a limited partnership			(1,217,039)
Investment in equity method investees		(708,129)
Investment in an equity security		(150,000)
Acquisition of a subsidiary	(3,055,432)
Loan (provided to) repayment from related parties	139,694	(387,549)	14,489
Loans provided to third parties	(1,032,219)	(3,725,211)
Loans repayment from third parties	1,806,772	1,075,098
Increase of cash in connection with acquisition of subsidiary	6,206
Net Cash Used in Investing Activities	(3,346,658)	(4,017,284)	(4,094,678)
Cash Flows from Financing Activities:
Proceeds from issuance of ordinary shares in connection with initial public offering, net of offering cost			11,886,363
Payment of expenses relating to initial public offerings			(388,709)
Proceeds from issuance of ordinary shares in connection with direct offering	1,850,744
Net Cash Provided by Financing Activities	1,850,744		11,497,654
Effect of exchange rate changes on cash and cash equivalents	(236,875)	(2,529)	875,258
Net (decrease) increase in cash and cash equivalents	(2,394,529)	(1,157,965)	7,240,395
Cash and cash equivalents at beginning of year	13,914,982	15,072,947	7,832,552
Cash and cash equivalents at end of year	11,520,453	13,914,982	15,072,947
Supplemental Cash Flow Information
Cash paid for interest expense
Cash paid for income tax	134,232	91,464	2,642
Noncash investing activities
Right of use assets obtained in exchange for operating lease obligations	1,774,723	555,639	37,919
Due from a third party for disposal of property and equipment	210,868
Acquisition of property and equipment by settlement of deposits for property and equipment	$ 160,940

Organization and Principal Acti

Organization and Principal Activities	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES	1. ORGANIZATION AND PRINCIPAL ACTIVITIES Zhongchao Inc. (“Zhongchao Cayman”, or the “Company”) is a holding company incorporated on April 16, 2019, under the laws of the Cayman Islands. The Company commenced operations on August 17, 2012, through its variable interest entity (“VIE”), Zhongchao Medical Technology (Shanghai) Limited (“Zhongchao Shanghai”), a limited liability company established under the laws of the PRC. The Company provides customized medical courses and customized medical training services to pharmaceutical enterprises, and not-for-profit organizations (“NFPs”) including medical associations, medical institutions, medical journals, medical foundations, hospitals and etc. in the PRC. The consolidated financial statements reflect the activities of Zhongchao Shanghai and each of the following entities: Name Background Ownership Zhongchao Group Inc. (“Zhongchao BVI”) ● A BVI company 100% owned by Zhongchao Cayman ● Incorporated on April 23, 2019 ● A holding company Zhongchao USA LLC (“Zhongchao USA”) ● A United States company 100% owned by Zhongchao Cayman ● Incorporated on 3 September, 2020 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed). Zhongchao Japan (“Zhongchao Japan”) ● A Japan company 100% owned by Zhongchao USA since December 2021. Before December 2021, 10% owned by Zhongchao USA and 90% owned by Mr. Weiguang Yang ● Incorporated on 1 October, 2020 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed). Zhongchao Group Limited (“Zhongchao HK”) ● A Hong Kong company 100% owned by Zhongchao BVI ● Incorporated on May 14, 2019 ● A holding company Beijing Zhongchao Zhongxing Technology Limited (“Zhongchao WFOE”) ● A PRC company and deemed a wholly foreign owned enterprise 100% owned by Zhongchao HK ● Incorporated on May 29, 2019 ● A holding company Zhongchao Shanghai ● A PRC limited liability company VIE of Beijing Zhongchao Zhongxing Technology Limited ● Incorporated on August 17, 2012 ● Engaged in technology development, technology transfer, and technical services in the field of medical technology, technical consulting in the field of network technology, and medical information consulting Shanghai Maidemu Cultural Communication Corp. (“Shanghai Maidemu”) ● A PRC limited liability company 100% owned by Zhongchao Shanghai ● Incorporated on March 12, 2015 ● Planning for cultural and artistic exchanges, designing, producing, acting for and publishing various kinds of advertisements, and medical consultation (no medical diagnosis and treatment activities allowed). Shanghai Huijing Information Technology Co., Ltd., (“Shanghai Huijing”) ● A PRC limited liability company 100% owned by Shanghai Maidemu ● Incorporated on September 28, 2016 ● Engaged in technology development, transfer, service and consulting in the fields of computer technology, graphic designing, website page designing, planning cultural and artistic exchanges. Shanghai Zhongxun Medical Technology Co., Ltd. (“Shanghai Zhongxun”) ● A PRC limited liability company 100% owned by Zhongchao Shanghai ● Incorporated on May 27, 2017 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed). Shanghai Zhongxin Medical Technology Co., Ltd (“Shanghai Zhongxin”) ● A PRC limited liability company 93.33% owned by Shanghai Zhongxun* ● Incorporated on October 10, 2018 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Beijing Zhongchao Boya Medical Technology Co., Ltd. (“Beijing Boya”) ● A PRC limited liability company 70% owned by Zhongchao Shanghai, and 30% owned by Mr. Zhengbo Ma on behalf of Zhongchao Shangha before December 8, 2021, and 30% owned by Shanghai Lingzhong Enterprise Management LLP on behalf of Zhongchao Shanghai after December 8, 2021 ● Incorporated on April 27, 2020 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Hainan Zhongteng Medical Technology Co., Ltd. (“Hainan Zhongteng”) ● A PRC limited liability company 100% owned by Beijing Boya ● Incorporated on July 16, 2021 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Zhixun Internet Hospital (Liaoning) Co., Ltd. (“Liaoning Zhixun”) ● A PRC limited liability company 100% owned by Beijing Boya ● Incorporated on July 6, 2020 ● Engaged in online hospital services, medical services, elderly nursing services, remote healthcare management services, healthcare consulting services, sales of medical appliances and other medical products. Shanghai Xinyuan Human Resources Co., Ltd. (“Shanghai Xinyuan”) ● A PRC limited liability company 100% owned by Shanghai Zhongxin ● Incorporated on January 13, 2021 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Hainan Muxin Medical Technology Co., Ltd. (“Hainan Muxin”) ● A PRC limited liability company 100% owned by Shanghai Zhongxin ● Incorporated on July 21, 2021 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Ningxia Zhongxin Internet Hospital Co., Ltd. (“Ningxia Zhongxin”) ● A PRC limited liability company 100% owned by Shanghai Zhongxin ● Incorporated on May 18, 2021 and cancelled on September 1, 2022 ● Engaged in online hospital operation, provide online medical service, online consultation, prescription information services, and medication retails. Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Chongqing Xinjiang”) ● A PRC limited liability company 100% owned by Shanghai Zhongxun ● Incorporated on January 18, 2022 ● Engaged in trading of patented drugs Beijing Yisuizhen Technology Co., Ltd. (“Beijing Yisuizhen”) ● A PRC limited liability company 100% owned by Hainan Muxin ● Incorporated on November 8, 2021 ● Acquired by the Company on August 31, 2022 ● Provision of online platform for communication between hospitals and patients West Angel (Beijing) Health Technology Co., Ltd. (“West Angel”) ● A PRC limited liability company 60% owned by Beijing Yisuizhen ● Incorporated on July 1, 2003 ● Acquired by the Company on August 31, 2022 ● Provision of online platform for communication between hospitals and patients * 51% of the equity interest owned by Shanghai Zhongxun before November 2020. Through certain entrustment agreements signed in November 2020, Mr. Weiguang Yang, Beijing Zhongchao Yixin Management Consulting Partnership, LLP (“Zhongchao Yixin”), and Beijing Zhongren Yixin Management Consulting Partnership, LLP (“Zhongren Yixin”), hold 19%, 20% and 10% of the equity interest of Shanghai Zhongxin on behalf of Shanghai Zhongxun, respectively. As a result, Shanghai Zhongxun owned 100% of Shanghai Zhongxin’s equity interest as of December 31, 2021. In the year of 2022, Mr. Weiguang Yang transferred 6.67% to four shareholders of West Angel, as a part of consideration to acquire 60% equity interest in West Angel. Shanghai Zhongxun owns 93.33% of Shanghai Zhongxin’s equity interest as of December 31, 2022. On August 14, 2019, Zhongchao WFOE entered into a series of agreements (the “VIE Agreements”) with Zhongchao Shanghai and the shareholders of Zhongchao Shanghai. The VIE Agreements allows Zhongchao Cayman to consolidate the financial statements and received the economic benefits of the operation results of Zhongchao Shanghai through the VIE Agreements. Under U.S. GAAP, for accounting purposes, Zhongchao Cayman was deemed to have a controlling financial interest in, and be the primary beneficiary of Zhongchao Shanghai, because pursuant to the VIE Agreements, the operations of Zhongchao Shanghai were solely for the benefit of Zhongchao WFOE and ultimately, Zhongchao Cayman. On August 14, 2019, Zhongchao Cayman completed a reorganization of entities under common control of Weiguang Yang, who owned a majority of the voting power of Zhongchao Cayman prior to the reorganization. Zhongchao Cayman, Zhongchao Group Inc. (“Zhongchao BVI”), and Zhongchao Group Limited (“Zhongchao HK”) were established as the holding companies of Zhongchao WFOE. Zhongchao WFOE is the primary beneficiary of Zhongchao Shanghai and its subsidiaries, and all of these entities are under common control which results in the consolidation of Zhongchao Shanghai and subsidiaries which have been accounted for as a reorganization of entities under common control at carrying value. The consolidated financial statements are prepared on the basis as if the reorganization became effective as of the beginning of the first period presented in the consolidated financial statements. Total assets and liabilities presented on the Company’s consolidated balance sheets and revenues, expenses, net incomes presented on consolidated statements of operations as well as the cash flows from operating, investing and financing activities presented on the consolidated statements of cash flows are substantially the financial positions, operations and cash flows of Zhongchao Shanghai and its subsidiaries. On August 15, 2019, Yantai Hanfujingfei Investment Centre (LP) (“Yantai HF”), a 6.25 % shareholder of Zhongchao Shanghai, planned to withdraw its equity interest in Zhongchao Shanghai (which is representative of 1,350,068 shares in Zhongchao Shanghai, among which 675,068 shares were issued by Zhongchao Shanghai and the remaining 675,000 shares were purchased from two existing shareholders), and to contribute the same amount of capital to Zhongchao Cayman directly. The Company and HF Capital Management Delta, Inc. (“HF Capital”), the sole member of which was the managing partner of Yantai HF , entered into a certain warrant agreement to purchase ordinary shares of the Company, pursuant to which the Company granted a warrant to HF Capital, who expects to exercise the warrant and receive the ordinary shares of the Company before the effective date and closing of the offering because these conditions are considered to be administrative procedures and there are no uncertainties of going through them. The warrant entitled HF Capital to purchase 1,350,068 Class A Ordinary Shares, representing 5.19% economic beneficial interest, or 1.31% of the voting ownership interest of the Company as of December 31, 2022, from the Company, if the following conditions are met: 1) All PRC governmental consent and approval required for HF Capital to exercise the warrant and payment of the capital contribution have been obtained, including without limitation, any approval or filing with respect to HF Capital’s investment into the Company, and payment by HF Capital of the capital contribution to the Company, and reasonable evidence thereof shall have been provided to the Company; 2) HF Capital has fully paid the capital contribution to Zhongchao Cayman; and 3) The Company released the paid-in capital of HF Capital from Zhongchao Shanghai The practice is solely a result of tax planning from HF Capital. As the warrant does not cause the Company to transfer or receive any assets, or exchange any other financial instruments on potentially favorable or unfavorable terms with shareholder. The warrant does not meet the definition of a financial instrument as defined in ASC 480 Distinguishing Liabilities from Equity On December 2, 2019, the registration of HF Capital’s withdrawal of its capital contribution in Zhongchao Shanghai was completed with local State Administration for Industry and Commerce. The paid-in capital of HF Capital in an amount of RMB20 million (approximately US$2.9 million) is currently being held in the corporate bank account of Zhongchao Shanghai and is to be deposited in a designated bank account mutually controlled by Zhongchao Shanghai and HF Capital after the completion of HF Capital’s ODI procedures and to be released as HF Capital’s capital contribution in Zhongchao Cayman. Class A Ordinary Shares issued and outstanding presented on the financial statements is reconciled with the number of shares legally as follows: December 31, December 31, Number of Class A Ordinary Shares legally issued and outstanding 19,181,355 18,103,355 Class A Ordinary Shares committed to be issued to HF Capital 1,350,068 1,350,068 Number of Class A Ordinary Shares outstanding and issued presented on the financial statements 20,531,423 19,453,423 VIE Agreements with Zhongchao Shanghai Due to the restrictions imposed by PRC laws and regulations on foreign ownership of companies engaged in value-added telecommunication services and certain other businesses, the Company operates its businesses in which foreign investment is restricted or prohibited in the PRC through certain PRC domestic companies. As such, Zhongchao Cayman consolidated Zhongchao Shanghai’s financial statements and received the economic benefits of the operation results of Zhongchao Shanghai through VIE Arrangements in lieu of direct equity ownership by the Company or any of its subsidiaries. Such VIE Arrangements consist of a series of six agreements (collectively, the “VIE Arrangements”), which were signed on August 14, 2019. On August 1, 2020, all shareholders of Zhongchao Shanghai, except Mr. Yang and Shanghai Xingzhong Investment Management LP (“Shanghai Xingzhong,”) decided to withdraw their capital contribution from Zhongchao Shanghai (the “Capital Reduction”). Given the effect of the Capital Reduction, Mr. Yang became the 76.4% shareholder of Zhongchao Shanghai with the remaining equity interests held by Shanghai Xingzhong. On September 10, 2020, Zhongchao WFOE, and Zhongchao Shanghai, and its shareholders signed a confirmation agreement to confirm that the VIE Agreements entered on August 14, 2019 have been terminated because of the Capital Reduction. Accordingly, on September 10, 2020, to clarify the legal effect of the Capital Reduction and to sustain the effective control over Zhongchao Shanghai by the Company, Mr. Yang and Shanghai Xingzhong, as the shareholders of Zhongchao Shanghai, signed a series of VIE agreements with Zhongchao WFOE, the terms of which are substantially the same as those of the VIE Agreements except the number of shareholders of Zhongchao Shanghai reduced to two (the “2020 VIE Agreements”). Upon entry into the 2020 VIE Agreements, the VIE Agreements, except for the Master Exclusive Service Agreement dated August 14, 2020, were expired. On September 9, 2021, Shanghai Xingzhong transferred its equity interest in Zhongchao Shanghai to Shanghai Xingban Enterprises Management Partnership (Limited Partnership) (“Shanghai Xingban”). On September 10, 2021, to clarify the legal effect of such share transfer and to sustain the Company’s ability to consolidate the financial results of Zhongchao Shanghai, Mr. Yang and Shanghai Xingban, as the shareholders collectively holding 100% equity interest in Zhongchao Shanghai, signed a series of VIE agreements with Zhongchao WFOE (the “2021 VIE Agreements”). Upon entry into the 2021 VIE Agreements, the 2020 VIE Agreements dated August 14, 2020, except for the Master Exclusive Service Agreement, were expired. The significant terms of the VIE Arrangements, 2020 VIE Arrangements and 2021 VIE Agreements by and among the Company’s wholly-owned subsidiary, Zhongchao WFOE, its consolidated variable interest entity, Zhongchao Shanghai, and the shareholders of Zhongchao Shanghai are as follows: Agreements that Provide Us Effective Control over Zhongchao Shanghai The Company’s wholly foreign owned entity, Zhongchao WFOE, has entered into the following agreements with Zhongchao Shanghai and its shareholders. Equity Interest Pledge Agreement Pursuant to the equity interest pledge agreement dated August 14, 2019, each shareholder of Zhongchao Shanghai (collectively “Shareholder”) has pledged all of its equity interest in Zhongchao Shanghai to guarantee the shareholder’s and Zhongchao Shanghai’s performance of their obligations under the master exclusive service agreement, business cooperation agreement, exclusive option agreement and proxy agreement and power of attorney. If Zhongchao Shanghai or any of its shareholders breaches their contractual obligations under these agreements, Zhongchao WFOE, as pledgee, will be entitled to dispose the pledged equity interest entirely or partially. Each of the shareholders of Zhongchao Shanghai agrees that, during the term of the equity interest pledge agreement, it will not dispose of the pledged equity interests or create or allow any encumbrance on the pledged equity interests without the prior written consent of Zhongchao WFOE. In addition, Zhongchao WFOE has the right to collect dividends generated by the pledged equity interest during the term of the pledge. The term of the initial equity interest pledge agreement is 20 years. After the expiration of the term of initial pledge registration, Zhongchao WFOE may at its sole discretion require the Shareholders to extend the term of the equity interest registration. Proxy Agreement and Power of Attorney Pursuant to the proxy agreement and power of attorney dated August 14, 2019, each shareholder of Zhongchao Shanghai has irrevocably appointed Zhongchao WFOE to act as such shareholder’s exclusive attorney-in-fact to exercise all shareholder rights, including, but not limited to, voting on all matters of Zhongchao Shanghai requiring shareholder approval, disposing of all or part of the shareholder’s equity interest in Zhongchao Shanghai, oversee and review Zhongchao Shanghai’s operation and financial information. Zhongchao WFOE is entitled to designate any person to act as such shareholder’s exclusive attorney-in-fact without notifying or the approval of such shareholder, and if required by PRC law, Zhongchao WFOE shall designate a PRC citizen to exercise such right. Each proxy agreement power of attorney will remain in force for so long as the Zhongchao Shanghai exists. The shareholders of Zhongchao Shanghai do not have the right to terminate this agreement or revoke the appointment of the attorney-in-fact without the prior written consent of Zhongchao WFOE Spouse Consent Letters Pursuant to the Spouse Consent Letters dated August 14, 2019, the spouse of each married shareholder of Zhongchao Shanghai, unconditionally and irrevocably agreed not to assert any rights over the equity interest in Zhongchao Shanghai held by and registered in the name of their spouse. In addition, each of them agreed to be bound by the VIE Arrangements described here if the spouse obtains any equity interest in Zhongchao Shanghai for any reason. Master Exclusive Service Agreement Under the master exclusive service agreement between Zhongchao WFOE and Zhongchao Shanghai dated August 14, 2019, Zhongchao WFOE has the exclusive right to provide Zhongchao Shanghai with technical support, consulting services and other services. Zhongchao WFOE has the right to designate and appoint, at its sole discretion, any entities affiliated with the Zhongchao WFOE to provide any and all services. The service fees are calculated and paid on a yearly basis and at the amount that equals to 100% of the consolidated net profits of Zhongchao Shanghai. Zhongchao WFOE may adjust the service fee at its discretion after taking into account multiple factors, such as the difficulty of the services provided, the time consumed, the content and commercial value of services provided and the market price of comparable services. Zhongchao WFOE owns the intellectual property rights arising out of the performance of this agreements. Zhongchao Shanghai shall seek approval from Zhongchao WFOE prior to entering into any contracts obtaining the same or similar services as provided under the Master Exclusive Service Agreement. This agreement will remain effective as long as Zhongchao Shanghai exists, unless Zhongchao WFOE advance written notice to Zhongchao Shanghai and its shareholders or upon the transfer of all the equity interest held by Zhongchao Shanghai’s shareholders to Zhongchao WFOE and/or a third party designated by Zhongchao WFOE. Agreements that Provide Us with the Option to Purchase the Equity Interest in Zhongchao Shanghai Business Cooperation Agreement Under the business cooperation agreement dated August 14, 2019, without Zhongchao WFOE’s prior written consent, Zhongchao Shanghai agrees not to engage in any transaction which may materially affect its asset, obligation, right or operation, including but not limited to: any activities not within its normal business scope, merger and acquisition, offering any loan to any third party and incurring any debt from any third party. Zhongchao Shanghai shall seek approval from Zhongchao WFOE prior to entering into any material contract, except the contracts executed in the ordinary course of business. Zhongchao Shanghai shall cause the persons designated by Zhongchao WFOE to be the directors and executive officers of Zhongchao Shanghai. This agreement will remain effective as long as Zhongchao Shanghai exists, unless Zhongchao WFOE advance written notice to Zhongchao Shanghai and its shareholders or upon the transfer of all the equity interest held by Zhongchao Shanghai’s shareholders to Zhongchao WFOE and/or a third party designated by Zhongchao WFOE. Exclusive Option Agreement Pursuant to the exclusive option agreement dated August 14, 2019, each shareholder of Zhongchao Shanghai has irrevocably granted Zhongchao WFOE an exclusive option to purchase, or have its designated person or persons to purchase, at its discretion, to the extent permitted under PRC law, all or part of the shareholder’s equity interests in Zhongchao Shanghai. The purchase price is equal to the lowest price allowable under PRC laws and regulations at the time of the transfer. Zhongchao Shanghai has agreed that without Zhongchao WFOE’s prior written consent, Zhongchao Shanghai shall cause the persons designated by Zhongchao WFOE to be the directors and executive officers of Zhongchao Shanghai, not amend its articles of association, increase or decrease the registered capital, sell or otherwise dispose of its assets or beneficial interest, create or allow any encumbrance on its assets or other beneficial interests, provide any loans to any third parties, enter into any material contract, merge with or acquire any other persons or make any investments, or distribute dividends to the shareholders. The shareholders of Zhongchao Shanghai have agreed that, without Zhongchao WFOE’s prior written consent, they will not dispose of their equity interests in Zhongchao Shanghai or create or allow any encumbrance on their equity interests. Moreover, without Zhongchao WFOE’s prior written consent, no dividend will be distributed to Zhongchao Shanghai’s shareholders, and if any of the shareholders receives any profit, interest, dividend or proceeds of share transfer or liquidation, the shareholder must give such profit, interest, dividend and proceeds to Zhongchao WFOE. These agreements will remain effective as long as Zhongchao Shanghai exists unless Zhongchao WFOE advance written notice to Zhongchao Shanghai and the shareholders or upon the transfer of all the equity interest held by the shareholders to Zhongchao WFOE and/or its designee. The Company has concluded that the Company is the primary beneficiary of Zhongchao Shanghai and its subsidiaries, and should consolidate their financial statements. The Company is the primary beneficiary based on the Proxy Agreement and Power of Attorney entered into as part of the VIE Agreements that each equity holder of Zhongchao Shanghai assigned their rights as a shareholder of Zhongchao Shanghai to Zhongchao WOFE. These rights include, but are not limited to, voting on all matters of Zhongchao Shanghai requiring shareholder approval, disposing of all or part of the shareholder’s equity interest in Zhongchao Shanghai, oversee and review Zhongchao Shanghai’s operation and financial information. As such, the Company, through Zhongchao WOFE, is deemed to hold all of the voting equity interest in Zhongchao Shanghai and its subsidiaries. For the periods presented, the Company has not provided any financial or other support to either Zhongchao Shanghai or its subsidiaries. However, pursuant to the Master Exclusive Services Agreement, the Company may provide complete technical support, consulting services and other services during the term of the VIE agreements. Though not explicit in the VIE agreements, the Company may provide financial support to Zhongchao Shanghai and its subsidiaries to meet its working capital requirements and capitalization purposes. The terms of the VIE Agreements and the Company’s plan of financial support to the VIE were considered in determining that the Company is the primary beneficiary of the VIE. Accordingly, the financial statements of the VIE are consolidated in the Company’s consolidated financial statements. Based on the foregoing VIE Agreements, Zhongchao WFOE consolidated the financial statements

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Principal of consolidation Affiliates are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of affiliates are included in the consolidated financial statements from the date that control commences until the date that control ceases. The consolidated financial statements include the accounts of Zhongchao Cayman, its subsidiaries and VIE and VIE’s subsidiaries, and Zhongchao Japan. These companies are controlled by a common controlling shareholder. Zhongchao Japan was acquired from the Company’s controlling shareholder in December 2021, such acquisition was accounted for as acquisition under common control and the Zhongchao Japan was consolidated from December 2021, and the comparative financial statement were prepared on a consolidated basis retrospectively from the date Zhongchao Japan was incorporated (i.e, October 30, 2020). In the consolidated financial statements, the assets and liabilities of Zhongchao Japan are presented at their carrying amount. The Company recognizes in equity any difference between the consideration paid and the net assets recognized. No goodwill or losses may be recognized on consolidation. The revenues, cost, operating expenses and other expenses are consolidated for the relevant periods to be presented in the financial statements as if the combination occurred on October 1, 2020. Zhongchao Japan’s historical financial statements have immaterial impact to the consolidated financial statements of the Company. All transactions and balances among the Company, its subsidiaries, VIE and Zhongchao Japan have been eliminated upon consolidation. Business combination and non-controlling interests The Company accounts for its business combinations using the acquisition method of accounting in accordance with ASC 805 “Business Combinations.” The cost of an acquisition is measured as the aggregate of the acquisition date fair value of the assets transferred to the sellers, liabilities incurred by the Company and equity instruments issued by the Company. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets acquired and liabilities assumed are measured separately at their fair values as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total costs of acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the acquisition date amounts of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the acquisition date amounts of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statements of operations and comprehensive (loss) income. During the measurement period, which can be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Subsequent to the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any further adjustments are recorded in the consolidated statements of operations and comprehensive (loss) income. In a business combination achieved in stages, the Company re-measures the previously held equity interest in the acquiree immediately before obtaining control at its acquisition date fair value and the re-measurement gain or loss, if any, is recognized in the consolidated statements of operations and comprehensive (loss) income. For the Company’s non-wholly owned subsidiaries, a noncontrolling interest is recognized to reflect the portion of equity that is not attributable, directly or indirectly, to the Company. Non-controlling interests represent the equity interests in the subsidiaries of the VIE that are not attributable, either directly or indirectly, to the VIE. For the Company’s consolidated financial statements, non-controlling interests represent minority shareholders’ 6.67% in Zhongxin and a minority shareholder’s 40% in West Angel, respectively, as of December 31, 2022. Non-controlling interests are presented as a separate line item in the equity section of the Company’s consolidated balance sheets and have been separately disclosed in the Company’s consolidated statements of operations and comprehensive (loss) income to distinguish the interests from that of the Company, its wholly-owned subsidiaries, VIE and VIE’s subsidiaries. Foreign currency translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing on the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates on the date of the balance sheet. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive (loss) income. The reporting currency of the Company and its subsidiaries is U.S. dollars (“US$”) and the accompanying consolidated financial statements have been expressed in US$. In general, for consolidation purposes, assets and liabilities of the Company and its subsidiaries whose functional currency is not the US$, are translated into US$, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of the Company and its subsidiaries are recorded as a separate component of accumulated other comprehensive (loss) income within the statement of shareholders’ equity. Translation of amounts from RMB into US$ has been made at the following exchange rates for the respective periods: December 31, December 31, Balance sheet items, except for equity accounts 6.8972 6.3726 For the Years Ended 2022 2021 2020 Items in the statements of operations and comprehensive (loss) income, and statements of cash flows 6.7290 6.4508 6.9020 No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at the rates used in translation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities on the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions using the currently available information. Changes in facts and circumstances may cause the Company to revise its estimates. The Company bases its estimates on past experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Estimates are used when accounting for items and matters including, but not limited to, fair value of the Company’s ordinary shares, fair value of the Company’s subsidiaries, determinations of the useful lives and valuation of long-lived assets, valuation of goodwill, estimates of allowances for doubtful accounts, valuation of deferred tax assets, and other provisions and contingencies. Fair value of financial instruments The Company’s financial instruments are accounted for at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are described below: Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value. As of December 31, 2022 and 2021, financial instruments of the Company comprised primarily current assets and current liabilities including cash and cash equivalents, accounts receivable, due from a related party, other receivables, loans receivable, accounts payable and other payables, which approximate their fair values because of the short-term nature of these instruments. Short-term investments are trading securities with observable market price in active market. They are classified as level 1 investment and are measured at fair value as of December 31, 2022 and 2021. Cash and cash equivalents Cash and cash equivalents primarily consist of bank deposits, as well as highly liquid investments, with original maturities of three months or less, which are unrestricted as to withdrawal and use. Short-term investments Short-term investments comprised of certain listed equity securities purchased through various open market transactions. Equity securities not measured by the equity method are carried at fair value with unrealized gains and losses recorded in the consolidated statements of operations and comprehensive (loss) income, according to ASC 321 “Investments — Equity Securities”. During the years ended December 31, 2022 and 2021, the Company purchased certain listed equity securities and accounted for such investments as “short-term investments” and subsequently measure the investments at fair value in the account of “other income, net”. Accounts receivable Accounts receivable are recorded at the gross amount less an allowance for any uncollectible accounts and do not bear interest. The Company provides customers with credit term ranging between one to six months, depending on credit assessment of customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history and the current economic conditions to make adjustments in the allowance when necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. During the years ended December 31, 2022, 2021 and 2020, the Company accrued provisions against doubtful accounts of $753,447, $1,449,827 and $336,367, respectively, among which $543,315, $1,449,827 and $336,367 were written off as the Company evaluated it is remote to collect the balance. As of December 31, 2022 and 2021, allowances for doubtful accounts against accounts receivable were $207,269 and $ nil Inventories Inventories of the Company consist of patented drugs. Inventories are stated at the lower of cost or net realizable value. Inventory costs include expenses that are directly or indirectly incurred in the purchase of patented drugs. Cost of inventories is determined using the weighted average cost method. Inventories are written down to estimated net realizable value, which could be impacted by certain factors including historical usage, expiration date, expected demand, anticipated sales price, new product development schedules, product obsolescence, customer concentrations and other factors. The Company continually evaluate the recoverability, and inventory provisions are recorded in the consolidated statements of operations and comprehensive (loss) income. For the years ended December 31, 2022, 2021 and 2020, the Company did not provide inventory provisions against patented drugs. Prepayments Prepayments represent amounts advanced to suppliers for providing services to the Company. The suppliers usually require advance payments when the Company orders service and the prepayments will be utilized to offset the Company’s future payments. These amounts are unsecured, non-interest bearing and generally short-term in nature. Investments in equity method investees In addition to the investment of investees over which the Company exercised significant influences, the Company also accounts for the investment in a limited partnership in which the Company holds more than minor equity interest (3% - 5%) in accordance with ASC 970-323-25-6 under the equity method of accounting. The Company applies the equity method to account for investment in a limited partnership and other investees, according to ASC 323 “Investments — Equity Method and Joint Ventures”, over which it has significant influence but does not own a controlling financial interest. Under the equity method, the Company’s share of the post-acquisition profits or losses of the equity investee is recognized in the consolidated statements of operations and comprehensive (loss) income. The Company records its share of the results of the equity investees on a one quarter in arrears basis. When the Company’s share of losses of the equity investee equals or exceeds its interest in the equity investee, the Company does not recognize further losses, unless the Company has incurred obligations or made payments or guarantees on behalf of the equity investee. The Company continually reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other-than-temporary. The primary factors the Company considers in its determination include the financial condition, operating performance and the prospects of the equity investee; other company specific information such as recent financing rounds; the geographic region, market and industry in which the equity investee operates, including consideration of the impact of the COVID-19 pandemic; and the length of time that the fair value of the investment is below its carrying value. If the decline in fair value is deemed to be other-than-temporary, the carrying value of the equity investee is written down to fair value. No impairment of was recognized for the years ended December 31, 2022, 2021 and 2020. Investments in an equity security Equity securities not accounted for using the equity method are carried at fair value with unrealized gains and losses recorded in the consolidated statements of operations and comprehensive (loss) income, according to ASC 321 “Investments — Equity Securities”, which the Company adopted beginning January 1, 2021. As of December 31, 2022, the Company had investment in one equity security. The Company elected to record an equity investment in privately held companies using the measurement alternative at cost, less impairment, with subsequent adjustments for observable price changes resulting from orderly transactions for identical or similar investments of the same issuer. As a practical expedient, the Company uses Net Asset Value (“NAV”) or its equivalent to measure the fair value of the investment in the fund. NAV is primarily determined based on information provided by financial institution. The equity investment in privately held companies accounted for using the measurement alternative are subject to periodic impairment reviews. The Company’s impairment analysis considers both qualitative and quantitative factors that may have a significant effect on the fair value of the equity security, including consideration of the impact of the COVID-19 pandemic. Property and equipment Property and equipment primarily consist of buildings, office equipment, and vehicle. Properties and equipment are stated at cost less accumulated depreciation less any provision required for impairment in value. Depreciation is computed using the straight-line method with residual value rate of 5% based on the estimated useful lives as follows: Land and buildings 7 - 21 years Office equipment 3 years Vehicle 4 years Leasehold improvements 5 years Costs of repairs and maintenance are expensed as incurred and asset improvements are capitalized. The cost and related accumulated depreciation of assets disposed of or retired are removed from the accounts, and any resulting gain or loss is recorded in other income, net in the consolidated statements of operations and comprehensive (loss) income. Prepayments for lease of land Prepayments for lease of land represent prepayments to the lessee for sub-lease of two land use rights. Prepayments for lease of land are carried at cost less accumulated amortization and any impairment loss. Amortization is provided against the cost of lease prepayments on a straight-line basis over the period of the rights, which are 16 years and 32 years, respectively. Intangible assets, net The Company acquired intangible assets through either purchase or acquisition in the business combination. Intangible assets acquired through business combinations are recognized as assets separate from goodwill if they satisfy either the “contractual-legal” or “separability” criterion. Intangible assets arising from business combinations are measured at fair value upon acquisition using valuation techniques such as discounted cash flow analysis. Major assumptions used in determining the fair value of these intangible assets include future growth rates and weighted average cost of capital. Separately identifiable intangible assets that have determinable lives continue to be amortized over their estimated useful lives using the straight-line method as follows: Purchased intangible assets are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue to be amortized over their estimated useful lives using the straight-line method based on their estimated useful lives as follows: Trademarks 10 years License 10 years Software 3 - 10 years Impairment of long-lived assets other than goodwill The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairment of long-lived assets was recognized for the years ended December 31, 2022, 2021 and 2020. Goodwill Goodwill represents the excess of the purchase consideration over the acquisition date amounts of the identifiable tangible and intangible assets acquired and liabilities assumed from the acquired entity as a result of the Company’s acquisitions of interests in its subsidiaries. Goodwill is not amortized but is tested for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that it might be impaired. The Company first assesses qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. In the qualitative assessment, the Company considers factors such as macroeconomic conditions, industry and market considerations, overall financial performance of the reporting unit, and other specific information related to the operations, business plans and strategies of the reporting unit, including consideration of the impact of the COVID-19 pandemic. Based on the qualitative assessment, if it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the quantitative impairment test is performed. No impairment of goodwill was recognized for the years ended December 31, 2022. Revenue recognition ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied. In accordance with ASC 606, revenues are recognized when control of the promised services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company identified each distinct service, or each series of distinct services that are substantially the same and that have the same pattern of transfer to the customer, as a performance obligation. Transaction price is allocated among different performance obligations identified in one contract. Timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable consisted of amounts invoiced and amounts for which revenue recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment. Advances from customers consists of payments received related to unsatisfied performance obligations at the end of the period. The Company applied a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. The Company has no material incremental costs for obtaining contracts with customers that the Company expects the benefit of those costs to be longer than one year. Medical training and education services The Company designs and provides medical training and education courses in both online and offline formats to physicians and allied healthcare professionals (the “training and education services”). The Company identifies a single performance obligation from contracts. The Company recognizes revenue at the point when the service was rendered. Payments received in advance from customers are recorded as “advance from customers” in the consolidated balance sheets. Advance from customers is recognized as revenue when the Company delivers the courses to its customers. Such advance payment received are non-refundable. In cases where fees are collected after the sales, revenue and accounts receivable are recognized upon delivery of medical training and education courses to the customers. The fees are fixed and determinable at the inception of the services. Offline medical training and education services courses – though customers can benefit from each service commitment, including design, production and presentation of medical courses, together with other readily available resources. The promises in the contracts with customers is integration of all of these service commitments. The Company concludes that these service commitments are highly dependent with each other, in the context of the contract term. Thus, these service commitments are not distinct from each other, and the Company combines all service commitments performed as a single performance obligation. In cases where the Company engages third party experts to provide presentation in medical courses, as the Company determines the contents and the participants, it has the ability to direct these experts to provide medical training services for the Company. Therefore, the Company is primarily responsible for fulfilling the promise to provide the medial courses and has the discretion in establishing the transaction price. The Company is a principal in the provision of services and recognizes revenues on a gross basis. Online medical training and education services courses – the promises in the contracts with customers consist of provision of online courses and presentation of the courses online for users to access for a period of time. The performance obligation of presentation of the courses online for users for a period of time is immaterial in the context of the contract because presentation of each course incurred no significant additional cost, nor will it occupy any significant resources of the Company, except for little digital space on the Company’s server, which is inconsequential. Therefore, the Company combines all service commitments performed as a single performance obligation. Patient management services in patient-aid projects The Company is engaged by NFPs and pharmaceutical enterprises to assist in the operation of patient-aid projects with a purpose to facilitate qualified patients to obtain free drug treatment from NFPs. The Company is responsible to provide doctors with access to training courses or training materials in connection with the drug treatment, review the completeness of application documents from patients, and other ad-hoc works (such programs with these plug-in features are hereinafter referred as the “patient-aid projects”). The arrangements are structured as fixed price contracts. The price is determined as stated in contracts and does not include any variable consideration. The Company identifies a single performance obligation from contracts and recognizes revenue over a period of time during which the Company provides the assistance to the NFPs till the earlier of the expiration of contract period or the free drugs are completely delivered. The Company uses an input-based method to measure the progress, by reference to the cost incurred in performing the obligation. The fees are fixed at the inception of the services and are collected either in advance or after the services are provided. Sales of patented drugs Starting from the year of 2022, the Company commenced sales of patented drugs to customers. The Company identified one performance obligation in the contracts with customers, and the transaction price is fixed. No sales incentives or return of goods is allowed only if there are quality issues. The Company recognized revenues upon sales of patented drugs upon acceptance of goods by customers. Other revenues The Company also provides consulting services to its customers, including drafting research papers and providing other academic supports, and facilitation services for hospitals and patients through online platform. The consulting services are accounted for as a single performance obligation and was recognized as revenue when the Company delivers services to the customers. Fees are generally collected after provision of services. The facilitation services are accounted for as a single performance obligation and was recognized as revenue when the Company completed facilitation services to the customers. For the years ended December 31, 2022, 2021, and 2020, other revenues accounted for 0.3%, 1.2% and 0% of consolidated revenues, respectively. The following table identifies the disaggregation of our revenue for the years ended December 31, 2022, 2021 and 2020, respectively. For the Years Ended 2022 2021 2020 Medical training and education services $ 6,604,487 $ 8,754,120 $ 10,543,852 Patient management services in patient-aid projects 6,288,602 7,343,343 7,445,936 Sales of patented drugs 1,216,096 - - Other revenues 42,331 199,307 - Total $ 14,151,516 $ 16,296,770 $ 17,989,788 Cost of revenues Cost of revenues was comprised of direct related costs incurred for preparation of online medical training courses and offline education seminars and patient-aid projects and cost of patented drugs. The cost of preparation of online medical training courses and offline education seminars and patient management services in patient-aid projects includes expenses of travelling and accommodation, seminar site-rental, video production and backdrop production, professional service fees charged by experts who provide online and offline seminars, salary and welfare expenses incurred by the key members of the editorial, design and production team, and labor cost for patient-aid projects. The travelling and accommodation expenses, including but not limited to the air-ticket expenses and hotel accommodation expenses, represented the costs arising from lecturers’ attendance and participation of the offline seminars. Other media expenses were incurred by the Company’s medical department for videos production, live streaming of the offline seminars, and materials collection to create online courses. These travelling, accommodation and media expenses are well budgeted before any agreements entered into by the Company and the customers. Therefore, such expenses are well covered by the customers under those agreements. The Company is not reimbursed by the customers separately. Employee benefits The full-time employees of the Company are entitled to staff welfare benefits including medical care, housing fund, pension benefits, unemployment insurance and other welfare, which are government mandated defined contribution plans. The Company is required to accrue for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant PRC regulations, and make cash contributions to the state-sponsored plans out of the amounts accrued. Total expenses for the plans were $817,345, $804,730, and $310,637 for the years ended December 31, 2022, 2021 and 2020, respectively. Research and development costs Research and development costs are mainly comprised of salary and welfare expenses for the Company’s IT department employees who work for the development of the Company’s platform and database, and software and related intellectual property expenses which were used to develop an extensive library of licensed content and medical database. For the years ended December 31, 2022, 2021, and 2020, the Company incurred research and development expenses of $411,524, $758,878, and $816,553, respectively. Advertising expenses Advertising expenses primarily include advertisement for the Company’s platform for online medical courses. Advertising costs are expensed as incurred and the total amounts charged to “selling and marketing expenses” in the consolidated statements of operations and comprehensive (loss) income were $989,900, $2,204,233, and $2,851,648 for the years ended December 31, 2022, 2021 and 2020, respectively. Share-based compensation Share-based awards granted to the Company’s employees and one non-employee are measured at fair value on grant date and measurement date, respectively, and share-based compensation expense is recognized (i) immediately at the grant date if no vesting conditions are required, or (ii) using the accelerated attribution method, net of estimated forfeitures, over the requisite service period. The fair value of restricted shares is determined with reference to the fair value of the underlying shares. At each date of measurement, the Company reviews internal and external sources of information to assist in the estimation of various attributes to determine the fair value of the share-based awards granted by the Company, including but not limited to the fair value of the Company ordinary shares, expected life, expected volatility and expected forfeiture rates. The Company is required to consider many factors and make certain assumptions during this assessment. If any of the assumptions used to determine the fair value of the share-based awards changes significantly, share-based compensation expense may differ materially in the future from that recorded in the current reporting period. Moreover, the estimates of fair value of the awards are not intended to predict actual future events or the value that ultimately will be realized by grantees who receive share-based awards, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by the Company for accounting purposes. Value added tax The Company is subject to value added tax (“VAT”) and related surcharges on the revenues earned for both sales of products and rendering of services in the PRC. The applicable rate of value added tax is 6% on services and 13% on sales of products. The related surcharges for revenues derived from provision medical co

Variable Interest Entities and

Variable Interest Entities and Other Consolidation Matters	12 Months Ended
	Dec. 31, 2022
Variable Interest Entities and Other Consolidation Matters [Member]
VARIABLE INTEREST ENTITIES AND OTHER CONSOLIDATION MATTERS	3. VARIABLE INTEREST ENTITIES AND OTHER CONSOLIDATION MATTERS On August 14, 2019, Zhongchao WFOE entered into VIE Agreements with Zhongchao Shanghai and its shareholders. The key terms of these VIE Agreements are summarized in “Note 1 - Organization and Principal Activities” above. VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. Zhongchao WFOE is deemed to have a controlling financial interest and be the primary beneficiary of Zhongchao Shanghai, because it has both of the following characteristics: 1. power to direct activities of Zhongchao Shanghai that most significantly impact its economic performance, and 2. obligation to absorb losses of the entity that could potentially be significant to Zhongchao Shanghai or right to receive benefits from the entity that could potentially be significant to Zhongchao Shanghai. In addition, as all of these VIE agreements are governed by PRC law and provide for the resolution of disputes through arbitration in the PRC, they would be interpreted in accordance with PRC law and any disputes would be resolved in accordance with PRC legal procedures. The legal environment in the PRC is not as developed as in other jurisdictions, such as the United States. As a result, uncertainties in the PRC legal system could further limit the Company’s ability to enforce these VIE agreements. Furthermore, these contracts may not be enforceable in China if PRC government authorities or courts take a view that such contracts contravene PRC laws and regulations or are otherwise not enforceable for public policy reasons. In the event the Company is unable to enforce these VIE Agreements, it may not be able to consolidate the financial statements of Zhongchao Shanghai and its ability to conduct its business may be materially and adversely affected. The Company had no operations but to consolidate the financial statements of Zhongchao Shanghai and its subsidiaries. Current regulations in China permit Zhongchao Shanghai to pay dividends to the Company only out of its accumulated distributable profits, if any, determined in accordance with their articles of association and PRC accounting standards and regulations. The ability of Zhongchao Shanghai to make dividends and other payments to the Company may be restricted by factors including changes in applicable foreign exchange and other laws and regulations. Risks of variable interest entity structure In the opinion of management, (i) the corporate structure of the Company is in compliance with existing PRC laws and regulations; (ii) the VIE Arrangements are valid and binding, and do not result in any violation of PRC laws or regulations currently in effect; and (iii) the business operations of WFOE and the VIE are in compliance with existing PRC laws and regulations in all material respects, except as disclosed in this Annual Report. However, there are substantial uncertainties regarding the interpretation and application of current and future PRC laws and regulations. Accordingly, the Company cannot be assured that PRC regulatory authorities will not ultimately take a contrary view to the foregoing opinion of its management. If the current corporate structure of the Company or the VIE Arrangements is found to be in violation of any existing or future PRC laws and regulations, the Company may be required to restructure its corporate structure and operations in the PRC to comply with changing and new PRC laws and regulations. In the opinion of management, the likelihood of loss in respect of the Company’s current corporate structure or the VIE Arrangements is remote based on current facts and circumstances. The following significant amounts of Zhongchao Shanghai and its subsidiaries are included in the accompanying consolidated financial statements as of December 31, 2022 and 2021, and for the years ended December 31, 2022, 2021 and 2020: December 31, December 31, ASSETS Cash and cash equivalents $ 4,500,379 $ 7,117,728 Accounts receivable 6,772,988 9,218,883 Inventories 189,106 - Other current assets 1,840,182 2,029,794 Investment in a limited partnership and an equity investee 1,179,300 1,993,285 Property and equipment, net 3,111,717 3,168,441 Goodwill 5,767,504 - Right of use assets 1,666,777 205,824 Deferred tax assets 1,800,493 2,025,043 Other noncurrent assets 1,456,322 414,105 Total Assets $ 28,284,768 $ 26,173,103 LIABILITIES Advances from customers $ 395,263 $ 7,432 Income tax payable 2,292,765 2,478,273 Operating lease liabilities, current and non-current 1,702,478 201,559 Due to Zhongchao Inc.* 762,962 599,347 Other current liabilities 992,558 1,011,371 Deferred tax liabilities 208,200 - Total Liabilities $ 6,354,226 $ 4,297,982 For the years ended December 31, 2022 2021 2020 Revenues $ 14,151,516 $ 16,096,769 $ 17,989,788 (Loss) Income from Operations $ (1,716,154 ) $ 418,235 $ 4,525,855 Net (Loss) Income $ (1,427,296 ) $ 838,838 $ 4,484,029 * The balances due from/to Zhongchao Inc., are eliminated on consolidation. As of December 31, 2022 and 2021, the VIE and its subsidiaries did not collateralize their assets for the obligation. Moreover the beneficial interest holders of the VIE and its subsidiaries had no recourse to the general credit of the Company or its subsidiaries.

Acquisition of Beijing Yisuizhe

Acquisition of Beijing Yisuizhen and its Subsidiary	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
ACQUISITION OF BEIJING YISUIZHEN AND ITS SUBSIDIARY	4. ACQUISITION OF BEIJING YISUIZHEN AND ITS SUBSIDIARY In November 2021, Beijing Yisuizhen was set up, over which the Company owned 47% effective equity interest with capital contribution of $708,129 (RMB 4,568,000),and accounted for the investment under equity method. In February 2022, Beijing Yisuizhen acquired 60% equity interest in West Angel and exercised control over West Angel, at cash consideration of RMB 25 million and a 6.67% share consideration in Shanghai Zhongxin at discounted price. Both Beijing Yisuizhen and West Angel are primarily engaged in technology development, consulting, communication, transfer, and promotion, software services, and health consulting services. In August 2022, the Company acquired additional equity interest in Beijing Yisuizhen and its subsidiary for a cash consideration of $3.1 million (RMB20.6 million) and a 6.67% share consideration in Shanghai Zhongxin at discounted price. Upon the completion of the transaction, the Company owns 100% equity interest in Beijing Yisuizhen and Beijing Yisuizhen became a consolidated subsidiary of the Company. The allocation of the purchase price as of the date of acquisition is summarized as follows: Net assets deficit assumed (i) $ (60,092 ) Software acquired in business combination (ii) 1,000,406 Goodwill 5,767,504 Deferred tax liabilities (234,225 ) Non-controlling interest (iii) (2,585,087 ) Foreign currency adjustments 120,261 $ 4,008,767 Total purchase price is comprised of Cash consideration $ 3,055,432 Fair value of previously held equity interests (iv) 708,129 Fair value of 6.67% equity interest in Zhongxin (v) 393,816 Less: cash from transfer of fair value of 6.67% equity interest in Zhongxin (v) (148,610 ) $ 4,008,767 (i) Net asset deficit assumed primarily included other current liabilities for operating expenses. (ii) Software acquired in the business combination had estimated useful life of 3 years. (iii) Fair value of the noncontrolling interests was estimated with reference to the market price per share as of the acquisition date. (iv) A gain of $850 in relation to the revaluation of the previously held equity interests was recorded in other income, net in the consolidated statements of operations and comprehensive (loss) income for the year ended December 31, 2022. The fair value of the previously held equity interests approximated the cost of investments as Beijing Yisuizhen has not commenced operations since its setup. (v) In exchange for the equity interest in Beijing Yisuizhen and West Angel, the Company also granted 6.67% equity interest in Shanghai Zhongxin, with fair value of $393,816 (RMB 2,713,000), to four shareholders of West Angel at cash consideration of $148,610 (RMB 1,000,000). The Company engaged a third party valuation team to estimate the fair value of equity interest of Shanghai Zhongxin. As of December 31, 2022, the four shareholders paid the cash consideration to Mr. Yang, the Chief Executive Officer of the Company. The Company recorded the outstanding balance in the account of due from related parties (Note 16).

Short-Term Investments

Short-Term Investments	12 Months Ended
	Dec. 31, 2022
Short-term Investments [Abstract]
SHORT-TERM INVESTMENTS	5. SHORT-TERM INVESTMENTS As of December 31, 2022 and 2021, the balance of short-term investments represented certain listed equity securities purchased through various open market transactions. The short-term investments are trading securities. They are initially recorded at cost, and subsequently measured at fair value with the changes in fair value recorded in other income, net in the consolidated statements of operations and comprehensive (loss) income. Loss from such short-term investment amounted to $240,489, $58,403 and $10,331 for the years ended December 31, 2022, 2021 and 2020, respectively.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2022
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	6. OTHER CURRENT ASSETS Other current assets consist of the following: December 31, December 31, Due from a third party (i) $ 205,726 $ - Office rental deposit 128,194 203,896 Interest receivable 88,720 78,950 Prepaid rental fees 803 45,607 Others 69,597 47,256 $ 493,040 $ 375,709 (i) During the year ended December 31, 2022, the Company sold one of its properties to a third party at cash consideration of $1,323,308 (Note 8), among which the third party paid $1,112,440. The Company recorded the remaining balance as “due from a third party” in the account of other current assets.

Loans Receivable

Loans Receivable	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
LOANS RECEIVABLE	7. LOANS RECEIVABLE Loans receivable consist of the following: December 31, December 31, Borrower A $ - $ 266,767 Borrower B - 199,893 Borrower C - 404,008 Borrower D 1,590,000 1,590,000 Borrower E 250,000 200,000 $ 1,840,000 $ 2,660,668 Borrower A, B and C During the year ended December 31, 2021, the Company made loans of RMB6,700,000 (approximately $1,038,631), RMB1,273,840 (approximately $197,470), RMB2,574,580 (approximately $399,110) to Borrowers A, B, and C, respectively. During the year ended December 31, 2021, the Company collected RMB 5,000,000 (approximately $775,098) from Borrower A. These loans were interest free. During the year ended December 31, 2022, the Company fully collected the loans receivables from Borrower A, B and C. Borrower D and E During the year ended December 31, 2021, the Company made loans of $1,890,000 and $200,000 to Borrower D and E, respectively. During the year ended December 31, 2021, the Company collected $300,000 from Borrower D. During the year ended December 31, 2022, the Company made loans of $200,000 to Borrower E. During the year ended December 31, 2022, the Company also collected $150,000 from Borrower E. These loans were interest free. In April 2022, Mr. Yang, the Chief Executive Officer of the Company, provided a guarantee on the borrowings to Borrower A, D and E, respectively, providing that Mr. Yang will repay the loans on behalf of the Borrower A, D and E if any of them failed to repay the loan. In December 2022, the Company extended borrowings for another six months and Mr. Yang provided an extended guarantee on the borrowings. As of the date of this report, the Company collected $1,590,000 from Borrower D, and settled the balance of $250,000 due from Borrower E with payables due to the borrower. As of the date of this report, the balance of loan receivable was zero.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	8. PROPERTY AND EQUIPMENT, NET Property and equipment, net consist of the following: December 31, December 31, Land and buildings $ 4,105,956 $ 4,063,587 Office equipment 79,082 460,525 Vehicle 32,535 35,213 Leasehold improvements 53,253 - Less: accumulated depreciation (379,879 ) (636,239 ) $ 3,890,947 $ 3,923,086 Depreciation expenses totaled $241,842, $312,898, and $176,111 for the years ended December 31, 2022, 2021 and 2020, respectively. In May 2021, the Company, through Ms. Lirong Yang, sister of the Company’s CEO, purchased a property for a total purchase price of approximately $1,397,317 in a public judicial auction in May 2021 to be used as office for Shanghai Maidemu, one of subsidiaries of the VIE of the Company. Pursuant to a real estate entrust agreement between Shanghai Maidemu and Ms. Yang, Shanghai Maidemu is considered ultimate ownership/beneficiary of this property. As of December 31, 2021, the Company obtained the property ownership certificate, but the property was illegally encroached by an outsider. Till March 2022, Jinan Intermediate People’s court has sent a letter to Beijing Higher People’s court, hoping that the eviction order of this case would be implemented by the Tongzhou District People’s court, where the property is located. During the year ended December 31, 2022, the Company sold the property to a third party for $1,323,308. The difference between the cash consideration and the net book value was recorded as “gain from disposal of property and equipment” in the account of “other income, net” in the consolidated statements of operations and comprehensive (loss) income.

Prepayments for Lease of Land

Prepayments for Lease of Land	12 Months Ended
	Dec. 31, 2022
Prepayments for Lease of Land [Abstract]
PREPAYMENTS FOR LEASE OF LAND	9. PREPAYMENTS FOR LEASE OF LAND Prepayments for lease of land consist of the followings: December 31, December 31, Prepayments for lease of land $ 401,031 $ 434,045 Less: accumulated amortization (96,244 ) (80,698 ) $ 304,787 $ 353,347 Amortization expenses totaled $22,226, $23,185, and $21,670 for the years ended December 31, 2022, 2021, and 2020, respectively.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS, NET	10. INTANGIBLE ASSETS, NET Intangible assets, net consist of the following: December 31, December 31, Software $ 1,041,872 $ 44,880 Trademark and license 11,133 12,050 Less: accumulated amortization (140,951 ) (26,671 ) $ 912,054 $ 30,259 For the years ended December 31, 2022, 2021 and 2020, amortization expense totaled $119,218, $5,525, and $4,544, respectively. The following is a schedule, by years, of amortization of intangible assets as of December 31, 2022: December 31, For the year ended December 31, 2023 $ 338,636 For the year ended December 31, 2024 338,636 For the year ended December 31, 2025 227,492 For the year ended December 31, 2026 5,105 For the year ended December 31, 2027 2,185 $ 912,054

Investments in Equity Method In

Investments in Equity Method Investees	12 Months Ended
	Dec. 31, 2022
Investment Company, Financial Highlights [Abstract]
INVESTMENTS IN EQUITY METHOD INVESTEES	11. INVESTMENTS IN EQUITY METHOD INVESTEES As of December 31, 2022 and 2021, the Company’s investments in equity investments were comprised of investment in one limited partnership and one equity investees were as the following: December 31, December 31, Ningbo Meishan Xinaishan Equity Investment Limited Partnership (“limited partnership”) (a) $ 1,179,300 $ 1,276,466 Beijing Yisuizhen (b) - 716,819 $ 1,179,300 $ 1,993,285 (a) On November 5, 2020, the Company entered into a five-year partnership agreement to invest $1,217,039, for 28% partnership interest in the limited partnership. The funds raised by the limited partnership are invested in one PRC private company engaged in immunotherapy. For the years ended December 31, 2022, 2021 and 2020, equity investment loss of $80, $13,758 and $25,622 have been recorded in other income, net for the Company’s share of the operating loss of the limited partnership. As of December 31, 2022 and 2021, no significant impairment indicators have been noted in connection with the investment. (b) On November 8, 2021, the Company newly set up Beijing Yisuizhen with other investors and acquired 47% equity interest at cash consideration of $708,129. In August 2022, the Company, through Hainan Muxin, acquired additional 53% equity interest in Beijing Yisuizhen, which was consolidated in the Company’s consolidated financial statements. Beijing Yisuizhen has not commenced operations. In addition, the Company did not note significant impairment indicators in connection with the investment.

Investment in an Equity Securit

Investment in an Equity Security	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN AN EQUITY SECURITY	12. INVESTMENT IN AN EQUITY SECURITY During the year ended December 31, 2021, the Company made an investment of $150,000 in Elite Ivy Investment LLC (“Elite Ivy”), accounting for 0.6% of the investee. Elite Ivy was mainly engaged in investments in equities, options, futures, debt securities and commodities, and interim investments in money market or equivalent instruments. The Company can withdraw the investment after six months of the investment. As a practical expedient, the Company uses Net Asset Value (“NAV”) or its equivalent to measure the fair value of the investment in the Elite Ivy. For the year ended December 31, 2022 and 2021, the Company recorded downward adjustments of $65,394 and $ nil The Company considers both qualitative and quantitative factors that may have a significant effect on the fair value of the equity security. For the year ended December 31, 2022 and 2021, the Company did not record impairment against the investment.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Other Current Assets [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: December 31, December 31, Other tax payable $ 379,712 $ 616,356 Accrued payroll 296,866 301,260 Customer deposits payable 83,367 - Other current liabilities 95,595 57,185 $ 855,540 $ 974,801 Other tax payable Other tax payables consist of the following: December 31, December 31, Value added tax payable $ 354,794 $ 579,516 Local taxes payable 24,918 36,840 $ 379,712 $ 616,356

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	14. INCOME TAXES Cayman Islands Under the current tax laws of the Cayman Islands, the Company is not subject to tax on income or capital gain. Additionally, upon payments of dividends to the shareholders, no Cayman Islands withholding tax will be imposed. British Virgin Islands Under the current tax laws of BVI, the Company’s subsidiary incorporated in the BVI is not subject to tax on income or capital gains. Hong Kong Zhongchao HK is incorporated in Hong Kong and is subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate for the first HKD$2 million of assessable profits is 8.25% and assessable profits above HKD$2 million will continue to be subject to the rate of 16.5% for corporations in Hong Kong, effective from the year of assessment 2018/2019. Before that, the applicable tax rate was 16.5% for corporations in Hong Kong. The Company did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Under Hong Kong tax laws, Zhongchao HK is exempted from income tax on its foreign-derived income and there are no withholding taxed in Hong Kong on remittance of dividends. USA Zhongchao USA is incorporated in the United States and is subject to a federal tax rate of 21%. Japan Under the current tax laws of Japan, Zhongchao Japan is incorporated in Japan and is subject to an income tax rate of 30%. For the year ended December 31, 2022, 2021 and 2020, Zhongchao Japan did not have taxable income. PRC For the year ended December 31, 2022, Zhongchao Shanghai and Beijing Branch of Shanghai Zhongxun is subject to PRC Enterprise Income Tax (“EIT”) on the taxable income in accordance with the relevant PRC income tax laws. The EIT rate for companies operating in the PRC is 25%. The Company’s other subsidiary and the VIE’s subsidiaries that are located in the PRC were qualified as Small and Micro-sized Enterprises (“SMEs”). For the year ended December 31, 2021 and 2020, Zhongchao Shanghai, Shanghai Maidemu, Shanghai Zhongxun, Shanghai Zhongxin, Huijing are subject to EIT rate of 25%. Hainan Zhongteng, located in Hainan Province, is subject to 15%. Beijing Boya, Shanghai Xinyuan and Hainan Muxin qualify as SMEs. Liaoning Zhixun was not qualified as a SMEs until fiscal year 2021. Qualified as a Software Development Enterprise and a High and New Technology Enterprise, Zhongchao Shanghai applied a preferential income tax rate of 12.5% for the year ended December 31, 2020. From January 1, 2021, Zhongchao Shanghai was subject to an EIT of 25%. SMEs are entitled to a reduced EIT rate of a reduced EIT rate of 20%, 87.5% reduction of taxable income for the first RMB1,000,000 taxable income and 75% reduction of taxable income between RMB 1,000,000 and RMB 3,000,000, and no reduction for the remaining taxable income for the year ended December 31, 2022; 87.5% reduction of taxable income for the first RMB1,000,000 taxable income and 50% reduction of taxable income between RMB 1,000,000 and RMB 3,000,000, and no reduction for the remaining taxable income for the year ended December 31, 2021; and 75% reduction of taxable income for the first RMB1,000,000 taxable income and 50% reduction of taxable income between RMB 1,000,000 and RMB 3,000,000, and no reduction for the remaining taxable income for the years ended before December 31, 2020. In September 2018, the State Taxation Administration of the PRC announced a preferential tax treatment for research and development expenses. Qualified entities are entitled to deduct 175% research and development expenses against income to reach a net operating income. The components of (loss) profit before income tax benefits (expenses) are summarized as follows: For the Years Ended 2022 2021 2020 PRC $ (1,243,361 ) $ 631,917 $ 4,976,484 Non-PRC (1,306,645 ) (742,670 ) (34,600 ) Total $ (2,550,006 ) $ (110,753 ) $ 4,941,884 Income tax benefits (expenses) consist of the following: For the Years Ended 2022 2021 2020 Current income tax expenses $ (138,188 ) $ (997,198 ) $ (543,211 ) Deferred income tax benefits (134,125 ) 1,346,616 58,424 Income tax benefits (expenses) $ (272,313 ) $ 349,418 $ (484,787 ) Below is a reconciliation of the statutory tax rate to the effective tax rate: For the Years Ended 2022 2021 2020 PRC statutory income tax rate 25 % 25 % 25 % Effect of different income tax rates in other jurisdictions (2.11 )% (34.11 )% 0 % Effect of preferential tax benefits 12.72 % 167.36 % (13.96 )% Effect of non-deductible expenses (1.22 )% (54.84 )% 0.35 % Effect of research and development credits 3.06 % 104.55 % (1.47 )% Effect of deferred tax rate change (34.22 )% 107.53 % 0 % Effect of changes in valuation allowance (13.91 )% 0 % 0 % Effective tax rate (10.68 )% 315.49 % 9.81 % Deferred tax assets as of December 31, 2022 and 2021 consist of the following: December 31, December 31, Deferred tax assets: Excess advertising expense $ 842,295 $ 911,799 Deferred Intangible assets amortization 25,790 33,590 Net operating loss carrying forward 1,052,209 1,079,962 Share-based compensation 178,764 156,928 Doubtful allowance against accounts receivable 51,817 - Changes in fair value of short-term investments 50,502 - Downward adjustments in investments in an equity security 13,733 - Lease liabilities 71,024 31,615 Less: Deferred tax liability - Right of use assets (81,910 ) (37,184 ) Less: Valuation allowance on deferred tax assets (339,495 ) - Deferred tax assets, net $ 1,864,729 $ 2,176,710 Deferred tax liability Software acquired in business combination 208,200 - $ 208,200 $ - As of December 31, 2022 and 2021, the Company had net operating loss carryforwards of $7,166,560 and $4,435,381, respectively. The net operating loss carryforwards $1,512,756 from Unite States and Hong Kong at December 31, 2022 could be carried forward indefinitely and shall not expire. The Company also has net operating loss carryforwards from PRC of $5,653,804 which expire starting in 2025 through 2027. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. As of December 31, 2022 and 2021, the Company recorded valuation allowance of $339,495 and $ nil The Company evaluates its valuation allowance requirements at end of each reporting period by reviewing all available evidence, both positive and negative, and considering whether, based on the weight of that evidence, a valuation allowance is needed. When circumstances cause a change in management’s judgement about the recoverability of deferred tax assets, the impact of the change on the valuation allowance is generally reflected in income from operations. The future realization of the tax benefit of an existing deductible temporary difference ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryforward period available under applicable tax law. As a result of the Tax Act, the Company has evaluated whether it has an additional tax liability from the Global Intangible Low Taxed Income (“GILTI”) inclusion on current earnings and profits of its foreign controlled corporations. The law also provides that corporate taxpayers may benefit from a 50% reduction in the GILTI inclusion, which effectively reduces the tax rate on the foreign income to 10.5%. The GILTI inclusion further provides for a foreign tax credit in connection with the foreign taxes paid. As of December 31, 2022 and 2021 the Company does not have any aggregated positive tested income; and as such, did not record a liability for GILTI tax. With the effective date of January 1, 2018, the Tax Act introduced a provision to tax global intangible low-taxed income (“GILTI”). The Company will account for future tax liability arising from Global Intangible Low-Taxed Income, if any, as a period cost.

(Loss) Earnings Per Share

(Loss) Earnings Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
(LOSS) EARNINGS PER SHARE	15. (LOSS) EARNINGS PER SHARE The following table sets forth the computation of basic and diluted (loss) earnings per ordinary share for the years ended December 31, 2022, 2021 and 2020, respectively: For the Years Ended 2022 2021 2020 Net (Loss) Income Attributable to Zhongchao Inc.’s shareholders $ (2,940,891 ) $ 238,665 $ 4,458,380 Weighted average number of ordinary share outstanding Basic and Diluted 25,997,757 24,938,513 24,425,637 (Loss) Earnings per share Basic and Diluted $ (0.113 ) $ 0.010 $ 0.183 On August 14, 2019, Zhongchao Cayman completed a reorganization of entities under common control of its then existing shareholders, who collectively owned a majority of the equity interests of Zhongchao Cayman prior to the reorganization. All references to numbers of common shares and per-share data in the consolidated financial statements have been adjusted to reflect such issuance of shares on a retrospective basis. In addition, the contingently issuable ordinary shares of 1,350,068 shares of Class A ordinary share underlying the warrant (Note 1) issued to one existing shareholder of Zhongchao Shanghai is included in calculation of basic and diluted weighted average number of ordinary share outstanding, as the Company does not expect any circumstances under which those shares would not be issued. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted (loss) earnings per share. For the years ended December 31, 2022, 2021 and 2020, the Company had no dilutive shares.

Related Party Transactions and

Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS AND BALANCES	16. RELATED PARTY TRANSACTIONS AND BALANCES 1) Nature of relationships with related parties Name Relationship with the Company Yang Weiguang Chairman of the Board, Chief Executive Officer Beijing Ougaini Trading Co., Ltd (“Beijing Ougaini”) Controlled by an immediate family member of Mr. Yang Weiguang Beijing Yisuizhen The Company owned 47% and 100% equity interest before and after August 17, 2022, respectively 2) Transactions with related parties Purchase from a related party For the Years Ended 2022 2021 2020 Beijing Ougaini $ 19,696 $ - $ - During the year ended December 31, 2022, the Company also prepaid $118,888 to Beijing Ougaini for purchase of products for employee welfare and marketing promotion. 3) Balances with related parties As of December 31, 2022 and 2021, the balances with related parties were as follows: December 31, December 31, Prepayments Beijing Ougaini $ 115,989 $ - Due from related parties Yang Weiguang (i) 226,178 - Beijing Yisuizhen (ii) - 392,305 $ 226,178 $ 392,305 (i) As of December 31, 2022, the Company had a balance of $226,178 due from Mr. Yang Weiguang. The balance was comprised of the following: - A balance of $144,986 arising from transfer of 6.67% equity interest of Shanghai Zhongxin to four former shareholders of West Angel, who paid consideration to Mr. Yang. (Note 4) - A balance of $81,192 as tuition paid on behalf of to Mr. Yang. As of the date of this report, Mr. Yang has repaid the above outstanding balances to the Company. (ii) As of December 31, 2021, the Company had a balance of $392,305 due from Beijing Yisuizhen, over which the Company owned 47% equity interest before August 17, 2022. The balance was a loan to the newly set up equity investee to support its working capital. The outstanding balance was repaid by Beijing Yisuizhen before business combination with the Company.

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
EQUITY	17. EQUITY Ordinary share The Company’s authorized share capital is 500,000,000 ordinary shares consisting of 450,000,000 Class A Ordinary Shares and 50,000,000 Class B ordinary shares, par value $0.0001 per share (each, a “Class B Ordinary Share”; collectively, “Class B Ordinary Shares”). On April 16, 2019, the Company issued 10,000 Class B Ordinary Shares. On August 14, 2019, the Company issued 14,752,352 Class A Ordinary Shares and 5,497,715 Class B Ordinary Shares. Holders of Class A Ordinary Shares and Class B Class A Ordinary Shares have the same rights except for voting and conversion rights. In respect of matters requiring a shareholder vote, each Class A Ordinary Share will be entitled to 1 vote and each Class B Ordinary Share will be entitled to 15 votes. The Class A Ordinary Shares are not convertible into shares of any other class. The Class B Ordinary Shares are convertible into Class A Ordinary Shares at any time after issuance at the option of the holder on a one to one basis. In addition, the Company was committed to issue 1,350,068 Class A Ordinary Shares to a 6.25 % shareholder of Zhongchao Shanghai, who is now in the progress of changing from a shareholder of Zhongchao Shanghai to a direct investor of Zhongchao Cayman (Note 1). The 1,350,068 Class A Ordinary Shares, representing 5.19% economic beneficial interest, or 1.31% of the voting ownership interest of the Company as of December 31, 2022, will be issued to the shareholder upon its capital contribution in Zhongchao Cayman and the Company released its paid-in capital in Zhongchao Shanghai. Such ordinary shares are included in the shares issued and outstanding as of December 31, 2022 and 2021 and in the calculation of earnings per share as such commitment to issue the shares is considered to be part the reorganization, and the shares are considered to be in existence from the time this shareholder made the investment. On February 26, 2020, the Company closed its initial public offering (IPO) on the Nasdaq Global Market. The Company offered 3,000,000 Class A Ordinary Shares in the IPO, par value $0.0001 per share, at $4.00 per share. In addition, the underwriters of the Company’s IPO have exercised in full their over-allotment option to purchase additional 315,000 Class A Ordinary Shares, at $4.00 per share. Gross proceeds of the Company’s IPO, including the proceeds from the sale of the over-allotment shares, totaled $13.26 million, before deducting underwriting discounts and other related expenses. On December 17, 2021, the Company, entered into a Sales Agreement with U.S. Tiger Securities, acting as Sales Agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, its Class A Ordinary Shares. Class A Ordinary Shares will be offered and sold pursuant to the prospectus supplement, dated December 17, 2021, to the Registration Statement on Form F-3 (File No. 333-256190) that forms a part of such Form F-3, for an aggregate offering price of up to $10,400,000. On January 6, 2022, the Sales Agent sold an aggregate of 1,060,000 Class A Ordinary Shares at an offering price of $1.8 per share for gross proceeds of $1,908,000. On October 10, 2022, September 13, 2021, and July 13, 2020, the Company granted an aggregation of 18,000 Class A Ordinary Shares to three non-executive directors as compensations for one year from March 1, 2022, 2021 and 2020, respectively. Restricted net assets The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its subsidiary or VIE. Relevant PRC statutory laws and regulations permit payments of dividends by Zhongchao WFOE and its subsidiaries only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations and after it has met the PRC requirements for appropriation to statutory reserves. Paid in capital of the PRC subsidiary and VIE and VIE’s subsidiaries included in the Company’s consolidated net assets are also non-distributable for dividend purposes. The results of operations reflected in the accompanying consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of Zhongchao WFOE, Zhongchao Shanghai and its subsidiaries. The Company is required to set aside at least 10% of their after-tax profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of its registered capital. In addition, the Company may allocate a portion of its after-tax profits based on PRC accounting standards to enterprise expansion fund and staff bonus and welfare fund at its discretion. The statutory reserve funds and the discretionary funds are not distributable as cash dividends. During the year ended December 31, 2022, 2021 and 2020 the Company accrued statutory reserve funds of $115,963, $397,552, and $385,689, respectively, which is 10% of the retained earnings of profit-making PRC subsidiaries, VIE or VIE’s subsidiaries as of December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022 and 2021, the Company had statutory reserve of $1,315,017 and $1,199,054, respectively. As of December 31, 2022 and 2021, the Company had net assets restricted in the aggregate, which include paid-in capital and statutory reserve of the Company’s PRC subsidiary and VIE and VIE’s subsidiaries that are included in the Company’s consolidated net assets, were approximately $13,314,132 and $13,198,169, respectively. The current PRC Enterprise Income Tax (“EIT”) Law also imposed a 10% withholding income tax for dividends distributed by a foreign invested enterprise to its immediate holding company outside China. A lower withholding tax rate will be applied if there is a tax treaty arrangement between mainland China and the jurisdiction of the foreign holding company. Holding companies in Hong Kong, for example, will be subject to a 5% withholding tax rate, subject to approval from the related PRC tax authorities. The ability of the Company’s PRC subsidiary and VIE and VIE’s subsidiaries to make dividends and other payments to the Company may also be restricted by changes in applicable foreign exchange and other laws and regulations. Foreign currency exchange regulation in China is primarily governed by the following rules: ● Foreign Exchange Administration Rules (1996), as amended in August 2008, or the Exchange Rules; ● Administration Rules of the Settlement, Sale and Payment of Foreign Exchange (1996), or the Administration Rules. Currently, under the Administration Rules, Renminbi is freely convertible for current account items, including the distribution of dividends, interest payments, trade and service related foreign exchange transactions, but not for capital account items, such as direct investments, loans, repatriation of investments and investments in securities outside of China, unless the prior approval of the State Administration of Foreign Exchange (the “SAFE”) is obtained and prior registration with the SAFE is made. Foreign-invested enterprises like Rise King WFOE that need foreign exchange for the distribution of profits to its shareholders may affect payment from their foreign exchange accounts or purchase and pay foreign exchange rates at the designated foreign exchange banks to their foreign shareholders by producing board resolutions for such profit distribution. Based on their needs, foreign-invested enterprises are permitted to open foreign exchange settlement accounts for current account receipts and payments of foreign exchange along with specialized accounts for capital account receipts and payments of foreign exchange at certain designated foreign exchange banks. Although the current Exchange Rules allow the convertibility of Chinese Renminbi into foreign currency for current account items, conversion of Chinese Renminbi into foreign exchange for capital items, such as foreign direct investment, loans or securities, requires the approval of SAFE, which is under the authority of the People’s Bank of China. These approvals, however, do not guarantee the availability of foreign currency conversion. The Company cannot be sure that it will be able to obtain all required conversion approvals for its operations or the Chinese regulatory authorities will not impose greater restrictions on the convertibility of Chinese Renminbi in the future. Currently, most of the Company’s retained earnings are generated in Renminbi. Any future restrictions on currency exchanges may limit the Company’s ability to use its retained earnings generated in Renminbi to make dividends or other payments in U.S. dollars or fund possible business activities outside China. As of December 31, 2022 and 2021, there was $ nil

Concentration Risk

Concentration Risk	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
CONCENTRATION RISK	18. CONCENTRATION RISK The Company has a concentration of its account receivables with specific customers. As of December 31, 2022, two customers accounted for 16.6% and11.6% of net accounts receivable, respectively. As of December 31, 2021, four customers accounted for 20.3%, 12.0%, 11.2% and 10.8% of net accounts receivable, respectively. For the year ended December 31, 2022, one customer accounted for approximately 15.9% of the total revenue, respectively. For the year ended December 31, 2021, three customers accounted for approximately 23.4%, 21.9% and 10.7% of the total revenue, respectively. For the year ended December 31, 2020, two customers accounted for approximately 26.9% and 19.7% of the total revenue, respectively. As of December 31, 2022 and 2021, the Company had insignificant balance of accounts payable and did not further assess the concentration risk of accounts payable. For the year ended December 31, 2022, one supplier accounted for approximately 22.9% of the total cost of revenue. For the year ended December 31, 2021, two suppliers accounted for approximately 16.4% and 10.2% of the total cost of revenue, respectively. For the year ended December 31, 2020, no supplier accounted for more than 10% of the total cost of revenue.

Share Based Compensation

Share Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
SHARE BASED COMPENSATION	19. SHARE BASED COMPENSATION The following table summarizes our unvested restricted share units: Number of Weighted- Unvested at December 31, 2020 427,076 $ 2.54 Granted 18,000 $ 1.64 Vested (18,000 ) $ 1.77 Unvested at December 31, 2021 427,076 $ 2.53 Granted 18,000 $ 1.16 Vested (137,880 ) $ 2.37 Unvested at December 31, 2022 307,196 $ 2.52 Among the outstanding restricted share units brought forward from December 31, 2020, 119,880 restricted shares were vest in May 2022. The remaining restricted share units will vest in January 2024 through February 2029, upon fulfilment of requisite service period by the employees. On September 13, 2021, the Company granted and issued 18,000 shares of restricted Class A Ordinary Shares to three non-executive directors as their compensation for the year from March 1, 2021. The restricted shares were vested in a straight line method over the service period, and will be transferable after a lock-up period of six months. As of December 31, 2021, 15,000 share were vested. The grant-date value of each restricted share units was $1.64 by reference to the closing price on September 13, 2021, and the total fair value of these restricted Class A Ordinary Share units aggregated $29,520. On October 10, 2022, the Company granted and issued 18,000 shares of restricted Class A Ordinary Shares to three non-executive directors as their compensation for the year from March 1, 2022. The restricted shares were vested in a straight line method over the service period, and will be transferable after a lock-up period of six months. As of December 31, 2022, 15,000 share were vested. The grant-date value of each restricted share units was $1.16 by reference to the closing price on October 10, 2022, and the total fair value of these restricted Class A Ordinary Share units aggregated $20,880. For the years ended December 31, 2022, 2021 and 2020, the Company had share-based compensation expenses of $160,777, $211,832, $168,350, respectively. As of December 31, 2022, the Company expected to incur share-based compensation expenses of $363,670 over a weighted average period of 3.9 years. The following table summarizes share-based compensation expenses charged to operating expenses: For the Years Ended 2022 2021 2020 Selling and marketing expenses $ 61,607 $ 111,997 $ 93,439 General and administrative expenses 99,170 99,826 74,911 Total share-based compensation expenses $ 160,777 $ 211,823 $ 168,350

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SEGMENT REPORTING	20. SEGMENT REPORTING The Company’s organizational structure is based on a number of factors that the CODM uses to evaluate, view and run its business operations which include, but not limited to, customer base, homogeneity of service and technology. The Company’s operating segments are based on such organizational structure and information reviewed by the CODM to evaluate the operating segment results. Based on management’s assessment, the Company has determined that it has two operating segments for the year ended December 31, 2022: (i) MDMOOC services, and (ii) sales of patented drugs. For the years ended December 31, 2021 and 2020, the Company determined that it had one reporting segment which is MDMOOC services. The following table presents major accounts of statements of operations by segments for the year ended December 31, 2022. MDMOOC Services Sales of patented drugs Total Revenues $ 12,935,420 $ 1,216,096 $ 14,151,516 Cost of revenues $ (7,166,871 ) $ (627,981 ) $ (7,794,852 ) Total operating expenses $ (9,153,373 ) $ (157,753 ) $ (9,311,126 ) Net Loss $ (2,409,212 ) $ (413,107 ) $ (2,822,319 ) December 31, December 31, Total assets MDMOOC services $ 37,183,491 $ 36,267,420 Sales of patented drugs 1,430,854 - $ 38,614,345 $ 36,267,420 Substantially all of the Company’s revenues are derived from China based on the geographical locations where services are provided to customers. In addition, the Company’s long-lived assets are substantially all located in and derived from China, and the amount of long-lived assets attributable to any individual other country is not material. Therefore, no geographical segments are presented.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	21. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be subject to certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes of these legal proceedings cannot be predicted, the Company does not believe these actions, in the aggregate, will have a material adverse impact on its financial position, results of operations or liquidity. Lease commitment As of December 31, 2022, the Company leases offices space under 12 non-cancelable operating lease arrangements, 9 of which had a term over 12 months. The Company considers those renewal or termination options that are reasonably certain to be exercised in the determination of the lease term and initial measurement of right of use assets and lease liabilities. Lease expense for lease payment is recognized on a straight-line basis over the lease term. The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company discounted lease payments based on an estimate of its incremental borrowing rate to present value. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The table below presents the operating lease related assets and liabilities recorded on the balance sheet. December 31, December 31, Rights of use lease assets $ 1,666,777 $ 205,824 Operating lease liabilities, current 480,633 88,968 Operating lease liabilities, noncurrent 1,221,845 112,591 Total operating lease liabilities $ 1,702,478 $ 201,559 As of December 31, 2022 and 2021, the weighted average remaining lease term was 1.82 and 1.38 years, respectively, and discount rates were 4.75% for all of the operating leases. Rental expense for the years ended December 31, 2022, 2021, and 2020 were $498,166, $426,152, and $312,675, respectively. For the years ended December 31, 2022, 2021 and 2020, the cash payment for amounts included in the measurement of lease liabilities was $409,595, $480,636, and $350,934, respectively. The following is a schedule, by years, of maturities of lease liabilities as of December 31, 2022: 2023 $ 550,915 2024 324,647 2025 317,927 2026 317,980 2027 and thereafter 397,475 Total lease payments 1,908,944 Less: imputed interest (206,466 ) Present value of lease liabilities $ 1,702,478

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	22. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the issuance of the consolidated financial statements and no other subsequent event is identified that would have required adjustment or disclosure in the consolidated financial statements.

Condensed financial information

Condensed financial information of the parent company	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Disclosure [Abstract]
CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY	23. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY The subsidiary did not pay any dividend to the parent company for the periods presented. For the purpose of presenting parent only financial information, the parent company records its investment in its subsidiary under the equity method of accounting. Such investment is presented on the separate condensed balance sheets of the parent company as “Investment in subsidiaries and the income of the subsidiary is presented as “share of income of subsidiary”. Certain information and footnote disclosures generally included in financial statements prepared in accordance with U.S. GAAP have been condensed and omitted. The parent company did not have significant capital and other commitments, long-term obligations, or guarantees as of December 31, 2022 and 2021. PARENT COMPANY BALANCE SHEETS December 31, December 31, ASSETS Cash and cash equivalents $ 4,110,216 $ 3,758,618 Due from subsidiaries 9,423,617 7,785,162 Investment in subsidiaries, VIE and VIE’s subsidiaries 16,906,213 21,022,642 Total Assets $ 30,440,046 $ 32,566,422 LIABILITIES AND EQUITY Total Liabilities $ - $ - Commitments and Contingencies Shareholders’ Equity Class A Ordinary Share (par value $0.0001 per share, 450,000,000 shares authorized; 20,531,423 and 19,453,423 shares issued and outstanding at December 31, 2022 and 2021, respectively) 2,054 1,946 Class B Ordinary Share (par value $0.0001 per share, 50,000,000 shares authorized; 5,497,715 and 5,497,715 shares issued and outstanding at December 31, 2022 and 2021, respectively) 550 550 Additional paid-in capital 24,998,388 22,986,975 Retained earnings 5,439,054 8,379,945 Accumulated comprehensive income - 1,197,006 Total Shareholders’ Equity 30,440,046 32,566,422 Total Liabilities and Shareholders’ Equity $ 30,440,046 $ 32,566,422 PARENT COMPANY STATEMENTS OF OPERATIONS For the Years Ended 2022 2021 2020 Equity in (loss) gain of subsidiaries $ (2,919,423 ) $ 266,775 $ 4,470,613 General and administrative expenses (23,193 ) (32,273 ) (12,233 ) Interest income 1,725 4,163 - Net (Loss) Income $ (2,940,891 ) 238,665 4,458,380 PARENT COMPANY STATEMENTS OF CASH FLOWS For the Years Ended 2022 2021 2020 Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities $ 139,309 $ 3,737 $ (700,873 ) Cash Flows from Investing Activities: Loans repaid from (made to) VIE and its subsidiaries (1,638,455 ) (3,400,000 ) (3,690,000 ) Net Cash Used in Investing Activities (1,638,455 ) (3,400,000 ) (3,690,000 ) Cash Flows from Financing Activities: Proceeds from issuance of common stocks in connection with initial public offering, net off issuance cost - - 11,497,654 Proceeds from issuance of common stocks in connection with direct offering, net off issuance cost 1,850,744 - - Net Cash Provided by Financing Activities 1,850,744 - 11,497,654 Net increase (decrease) in cash and cash equivalents 351,598 (3,396,263 ) 7,106,781 Cash and cash equivalents at beginning of year 3,758,618 7,154,881 48,100 Cash and cash equivalents at end of year $ 4,110,216 $ 3,758,618 $ 7,154,881

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Principal of consolidation	Principal of consolidation Affiliates are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of affiliates are included in the consolidated financial statements from the date that control commences until the date that control ceases. The consolidated financial statements include the accounts of Zhongchao Cayman, its subsidiaries and VIE and VIE’s subsidiaries, and Zhongchao Japan. These companies are controlled by a common controlling shareholder. Zhongchao Japan was acquired from the Company’s controlling shareholder in December 2021, such acquisition was accounted for as acquisition under common control and the Zhongchao Japan was consolidated from December 2021, and the comparative financial statement were prepared on a consolidated basis retrospectively from the date Zhongchao Japan was incorporated (i.e, October 30, 2020). In the consolidated financial statements, the assets and liabilities of Zhongchao Japan are presented at their carrying amount. The Company recognizes in equity any difference between the consideration paid and the net assets recognized. No goodwill or losses may be recognized on consolidation. The revenues, cost, operating expenses and other expenses are consolidated for the relevant periods to be presented in the financial statements as if the combination occurred on October 1, 2020. Zhongchao Japan’s historical financial statements have immaterial impact to the consolidated financial statements of the Company. All transactions and balances among the Company, its subsidiaries, VIE and Zhongchao Japan have been eliminated upon consolidation.
Business combination and non-controlling interests	Business combination and non-controlling interests The Company accounts for its business combinations using the acquisition method of accounting in accordance with ASC 805 “Business Combinations.” The cost of an acquisition is measured as the aggregate of the acquisition date fair value of the assets transferred to the sellers, liabilities incurred by the Company and equity instruments issued by the Company. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets acquired and liabilities assumed are measured separately at their fair values as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total costs of acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the acquisition date amounts of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the acquisition date amounts of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statements of operations and comprehensive (loss) income. During the measurement period, which can be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Subsequent to the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any further adjustments are recorded in the consolidated statements of operations and comprehensive (loss) income. In a business combination achieved in stages, the Company re-measures the previously held equity interest in the acquiree immediately before obtaining control at its acquisition date fair value and the re-measurement gain or loss, if any, is recognized in the consolidated statements of operations and comprehensive (loss) income. For the Company’s non-wholly owned subsidiaries, a noncontrolling interest is recognized to reflect the portion of equity that is not attributable, directly or indirectly, to the Company. Non-controlling interests represent the equity interests in the subsidiaries of the VIE that are not attributable, either directly or indirectly, to the VIE. For the Company’s consolidated financial statements, non-controlling interests represent minority shareholders’ 6.67% in Zhongxin and a minority shareholder’s 40% in West Angel, respectively, as of December 31, 2022. Non-controlling interests are presented as a separate line item in the equity section of the Company’s consolidated balance sheets and have been separately disclosed in the Company’s consolidated statements of operations and comprehensive (loss) income to distinguish the interests from that of the Company, its wholly-owned subsidiaries, VIE and VIE’s subsidiaries.
Foreign currency translation	Foreign currency translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing on the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates on the date of the balance sheet. The resulting exchange differences are recorded in the consolidated statements of operations and comprehensive (loss) income. The reporting currency of the Company and its subsidiaries is U.S. dollars (“US$”) and the accompanying consolidated financial statements have been expressed in US$. In general, for consolidation purposes, assets and liabilities of the Company and its subsidiaries whose functional currency is not the US$, are translated into US$, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of the Company and its subsidiaries are recorded as a separate component of accumulated other comprehensive (loss) income within the statement of shareholders’ equity. Translation of amounts from RMB into US$ has been made at the following exchange rates for the respective periods: December 31, December 31, Balance sheet items, except for equity accounts 6.8972 6.3726 For the Years Ended 2022 2021 2020 Items in the statements of operations and comprehensive (loss) income, and statements of cash flows 6.7290 6.4508 6.9020 No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at the rates used in translation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities on the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, management reviews these estimates and assumptions using the currently available information. Changes in facts and circumstances may cause the Company to revise its estimates. The Company bases its estimates on past experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Estimates are used when accounting for items and matters including, but not limited to, fair value of the Company’s ordinary shares, fair value of the Company’s subsidiaries, determinations of the useful lives and valuation of long-lived assets, valuation of goodwill, estimates of allowances for doubtful accounts, valuation of deferred tax assets, and other provisions and contingencies.
Fair value of financial instruments	Fair value of financial instruments The Company’s financial instruments are accounted for at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are described below: Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value. As of December 31, 2022 and 2021, financial instruments of the Company comprised primarily current assets and current liabilities including cash and cash equivalents, accounts receivable, due from a related party, other receivables, loans receivable, accounts payable and other payables, which approximate their fair values because of the short-term nature of these instruments. Short-term investments are trading securities with observable market price in active market. They are classified as level 1 investment and are measured at fair value as of December 31, 2022 and 2021.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents primarily consist of bank deposits, as well as highly liquid investments, with original maturities of three months or less, which are unrestricted as to withdrawal and use.
Short-term investments	Short-term investments Short-term investments comprised of certain listed equity securities purchased through various open market transactions. Equity securities not measured by the equity method are carried at fair value with unrealized gains and losses recorded in the consolidated statements of operations and comprehensive (loss) income, according to ASC 321 “Investments — Equity Securities”. During the years ended December 31, 2022 and 2021, the Company purchased certain listed equity securities and accounted for such investments as “short-term investments” and subsequently measure the investments at fair value in the account of “other income, net”.
Accounts receivable	Accounts receivable Accounts receivable are recorded at the gross amount less an allowance for any uncollectible accounts and do not bear interest. The Company provides customers with credit term ranging between one to six months, depending on credit assessment of customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history and the current economic conditions to make adjustments in the allowance when necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. During the years ended December 31, 2022, 2021 and 2020, the Company accrued provisions against doubtful accounts of $753,447, $1,449,827 and $336,367, respectively, among which $543,315, $1,449,827 and $336,367 were written off as the Company evaluated it is remote to collect the balance. As of December 31, 2022 and 2021, allowances for doubtful accounts against accounts receivable were $207,269 and $ nil
Inventories	Inventories Inventories of the Company consist of patented drugs. Inventories are stated at the lower of cost or net realizable value. Inventory costs include expenses that are directly or indirectly incurred in the purchase of patented drugs. Cost of inventories is determined using the weighted average cost method. Inventories are written down to estimated net realizable value, which could be impacted by certain factors including historical usage, expiration date, expected demand, anticipated sales price, new product development schedules, product obsolescence, customer concentrations and other factors. The Company continually evaluate the recoverability, and inventory provisions are recorded in the consolidated statements of operations and comprehensive (loss) income. For the years ended December 31, 2022, 2021 and 2020, the Company did not provide inventory provisions against patented drugs.
Prepayments	Prepayments Prepayments represent amounts advanced to suppliers for providing services to the Company. The suppliers usually require advance payments when the Company orders service and the prepayments will be utilized to offset the Company’s future payments. These amounts are unsecured, non-interest bearing and generally short-term in nature.
Investments in equity method investees	Investments in equity method investees In addition to the investment of investees over which the Company exercised significant influences, the Company also accounts for the investment in a limited partnership in which the Company holds more than minor equity interest (3% - 5%) in accordance with ASC 970-323-25-6 under the equity method of accounting. The Company applies the equity method to account for investment in a limited partnership and other investees, according to ASC 323 “Investments — Equity Method and Joint Ventures”, over which it has significant influence but does not own a controlling financial interest. Under the equity method, the Company’s share of the post-acquisition profits or losses of the equity investee is recognized in the consolidated statements of operations and comprehensive (loss) income. The Company records its share of the results of the equity investees on a one quarter in arrears basis. When the Company’s share of losses of the equity investee equals or exceeds its interest in the equity investee, the Company does not recognize further losses, unless the Company has incurred obligations or made payments or guarantees on behalf of the equity investee. The Company continually reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other-than-temporary. The primary factors the Company considers in its determination include the financial condition, operating performance and the prospects of the equity investee; other company specific information such as recent financing rounds; the geographic region, market and industry in which the equity investee operates, including consideration of the impact of the COVID-19 pandemic; and the length of time that the fair value of the investment is below its carrying value. If the decline in fair value is deemed to be other-than-temporary, the carrying value of the equity investee is written down to fair value. No impairment of was recognized for the years ended December 31, 2022, 2021 and 2020.
Investments in an equity security	Investments in an equity security Equity securities not accounted for using the equity method are carried at fair value with unrealized gains and losses recorded in the consolidated statements of operations and comprehensive (loss) income, according to ASC 321 “Investments — Equity Securities”, which the Company adopted beginning January 1, 2021. As of December 31, 2022, the Company had investment in one equity security. The Company elected to record an equity investment in privately held companies using the measurement alternative at cost, less impairment, with subsequent adjustments for observable price changes resulting from orderly transactions for identical or similar investments of the same issuer. As a practical expedient, the Company uses Net Asset Value (“NAV”) or its equivalent to measure the fair value of the investment in the fund. NAV is primarily determined based on information provided by financial institution. The equity investment in privately held companies accounted for using the measurement alternative are subject to periodic impairment reviews. The Company’s impairment analysis considers both qualitative and quantitative factors that may have a significant effect on the fair value of the equity security, including consideration of the impact of the COVID-19 pandemic.
Property and equipment	Property and equipment Property and equipment primarily consist of buildings, office equipment, and vehicle. Properties and equipment are stated at cost less accumulated depreciation less any provision required for impairment in value. Depreciation is computed using the straight-line method with residual value rate of 5% based on the estimated useful lives as follows: Land and buildings 7 - 21 years Office equipment 3 years Vehicle 4 years Leasehold improvements 5 years Costs of repairs and maintenance are expensed as incurred and asset improvements are capitalized. The cost and related accumulated depreciation of assets disposed of or retired are removed from the accounts, and any resulting gain or loss is recorded in other income, net in the consolidated statements of operations and comprehensive (loss) income.
Prepayments for lease of land	Prepayments for lease of land Prepayments for lease of land represent prepayments to the lessee for sub-lease of two land use rights. Prepayments for lease of land are carried at cost less accumulated amortization and any impairment loss. Amortization is provided against the cost of lease prepayments on a straight-line basis over the period of the rights, which are 16 years and 32 years, respectively.
Intangible assets, net	Intangible assets, net The Company acquired intangible assets through either purchase or acquisition in the business combination. Intangible assets acquired through business combinations are recognized as assets separate from goodwill if they satisfy either the “contractual-legal” or “separability” criterion. Intangible assets arising from business combinations are measured at fair value upon acquisition using valuation techniques such as discounted cash flow analysis. Major assumptions used in determining the fair value of these intangible assets include future growth rates and weighted average cost of capital. Separately identifiable intangible assets that have determinable lives continue to be amortized over their estimated useful lives using the straight-line method as follows: Purchased intangible assets are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue to be amortized over their estimated useful lives using the straight-line method based on their estimated useful lives as follows: Trademarks 10 years License 10 years Software 3 - 10 years
Impairment of long-lived assets other than goodwill	Impairment of long-lived assets other than goodwill The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairment of long-lived assets was recognized for the years ended December 31, 2022, 2021 and 2020.
Goodwill	Goodwill Goodwill represents the excess of the purchase consideration over the acquisition date amounts of the identifiable tangible and intangible assets acquired and liabilities assumed from the acquired entity as a result of the Company’s acquisitions of interests in its subsidiaries. Goodwill is not amortized but is tested for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that it might be impaired. The Company first assesses qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. In the qualitative assessment, the Company considers factors such as macroeconomic conditions, industry and market considerations, overall financial performance of the reporting unit, and other specific information related to the operations, business plans and strategies of the reporting unit, including consideration of the impact of the COVID-19 pandemic. Based on the qualitative assessment, if it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the quantitative impairment test is performed. No impairment of goodwill was recognized for the years ended December 31, 2022.
Revenue recognition	Revenue recognition ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied. In accordance with ASC 606, revenues are recognized when control of the promised services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. The Company identified each distinct service, or each series of distinct services that are substantially the same and that have the same pattern of transfer to the customer, as a performance obligation. Transaction price is allocated among different performance obligations identified in one contract. Timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable consisted of amounts invoiced and amounts for which revenue recognized prior to invoicing when the Company has satisfied its performance obligation and has the unconditional right to payment. Advances from customers consists of payments received related to unsatisfied performance obligations at the end of the period. The Company applied a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. The Company has no material incremental costs for obtaining contracts with customers that the Company expects the benefit of those costs to be longer than one year. Medical training and education services The Company designs and provides medical training and education courses in both online and offline formats to physicians and allied healthcare professionals (the “training and education services”). The Company identifies a single performance obligation from contracts. The Company recognizes revenue at the point when the service was rendered. Payments received in advance from customers are recorded as “advance from customers” in the consolidated balance sheets. Advance from customers is recognized as revenue when the Company delivers the courses to its customers. Such advance payment received are non-refundable. In cases where fees are collected after the sales, revenue and accounts receivable are recognized upon delivery of medical training and education courses to the customers. The fees are fixed and determinable at the inception of the services. Offline medical training and education services courses – though customers can benefit from each service commitment, including design, production and presentation of medical courses, together with other readily available resources. The promises in the contracts with customers is integration of all of these service commitments. The Company concludes that these service commitments are highly dependent with each other, in the context of the contract term. Thus, these service commitments are not distinct from each other, and the Company combines all service commitments performed as a single performance obligation. In cases where the Company engages third party experts to provide presentation in medical courses, as the Company determines the contents and the participants, it has the ability to direct these experts to provide medical training services for the Company. Therefore, the Company is primarily responsible for fulfilling the promise to provide the medial courses and has the discretion in establishing the transaction price. The Company is a principal in the provision of services and recognizes revenues on a gross basis. Online medical training and education services courses – the promises in the contracts with customers consist of provision of online courses and presentation of the courses online for users to access for a period of time. The performance obligation of presentation of the courses online for users for a period of time is immaterial in the context of the contract because presentation of each course incurred no significant additional cost, nor will it occupy any significant resources of the Company, except for little digital space on the Company’s server, which is inconsequential. Therefore, the Company combines all service commitments performed as a single performance obligation. Patient management services in patient-aid projects The Company is engaged by NFPs and pharmaceutical enterprises to assist in the operation of patient-aid projects with a purpose to facilitate qualified patients to obtain free drug treatment from NFPs. The Company is responsible to provide doctors with access to training courses or training materials in connection with the drug treatment, review the completeness of application documents from patients, and other ad-hoc works (such programs with these plug-in features are hereinafter referred as the “patient-aid projects”). The arrangements are structured as fixed price contracts. The price is determined as stated in contracts and does not include any variable consideration. The Company identifies a single performance obligation from contracts and recognizes revenue over a period of time during which the Company provides the assistance to the NFPs till the earlier of the expiration of contract period or the free drugs are completely delivered. The Company uses an input-based method to measure the progress, by reference to the cost incurred in performing the obligation. The fees are fixed at the inception of the services and are collected either in advance or after the services are provided. Sales of patented drugs Starting from the year of 2022, the Company commenced sales of patented drugs to customers. The Company identified one performance obligation in the contracts with customers, and the transaction price is fixed. No sales incentives or return of goods is allowed only if there are quality issues. The Company recognized revenues upon sales of patented drugs upon acceptance of goods by customers. Other revenues The Company also provides consulting services to its customers, including drafting research papers and providing other academic supports, and facilitation services for hospitals and patients through online platform. The consulting services are accounted for as a single performance obligation and was recognized as revenue when the Company delivers services to the customers. Fees are generally collected after provision of services. The facilitation services are accounted for as a single performance obligation and was recognized as revenue when the Company completed facilitation services to the customers. For the years ended December 31, 2022, 2021, and 2020, other revenues accounted for 0.3%, 1.2% and 0% of consolidated revenues, respectively. The following table identifies the disaggregation of our revenue for the years ended December 31, 2022, 2021 and 2020, respectively. For the Years Ended 2022 2021 2020 Medical training and education services $ 6,604,487 $ 8,754,120 $ 10,543,852 Patient management services in patient-aid projects 6,288,602 7,343,343 7,445,936 Sales of patented drugs 1,216,096 - - Other revenues 42,331 199,307 - Total $ 14,151,516 $ 16,296,770 $ 17,989,788
Cost of revenues	Cost of revenues Cost of revenues was comprised of direct related costs incurred for preparation of online medical training courses and offline education seminars and patient-aid projects and cost of patented drugs. The cost of preparation of online medical training courses and offline education seminars and patient management services in patient-aid projects includes expenses of travelling and accommodation, seminar site-rental, video production and backdrop production, professional service fees charged by experts who provide online and offline seminars, salary and welfare expenses incurred by the key members of the editorial, design and production team, and labor cost for patient-aid projects. The travelling and accommodation expenses, including but not limited to the air-ticket expenses and hotel accommodation expenses, represented the costs arising from lecturers’ attendance and participation of the offline seminars. Other media expenses were incurred by the Company’s medical department for videos production, live streaming of the offline seminars, and materials collection to create online courses. These travelling, accommodation and media expenses are well budgeted before any agreements entered into by the Company and the customers. Therefore, such expenses are well covered by the customers under those agreements. The Company is not reimbursed by the customers separately.
Employee benefits	Employee benefits The full-time employees of the Company are entitled to staff welfare benefits including medical care, housing fund, pension benefits, unemployment insurance and other welfare, which are government mandated defined contribution plans. The Company is required to accrue for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant PRC regulations, and make cash contributions to the state-sponsored plans out of the amounts accrued. Total expenses for the plans were $817,345, $804,730, and $310,637 for the years ended December 31, 2022, 2021 and 2020, respectively.
Research and development costs	Research and development costs Research and development costs are mainly comprised of salary and welfare expenses for the Company’s IT department employees who work for the development of the Company’s platform and database, and software and related intellectual property expenses which were used to develop an extensive library of licensed content and medical database. For the years ended December 31, 2022, 2021, and 2020, the Company incurred research and development expenses of $411,524, $758,878, and $816,553, respectively.
Advertising expenses	Advertising expenses Advertising expenses primarily include advertisement for the Company’s platform for online medical courses. Advertising costs are expensed as incurred and the total amounts charged to “selling and marketing expenses” in the consolidated statements of operations and comprehensive (loss) income were $989,900, $2,204,233, and $2,851,648 for the years ended December 31, 2022, 2021 and 2020, respectively.
Share-based compensation	Share-based compensation Share-based awards granted to the Company’s employees and one non-employee are measured at fair value on grant date and measurement date, respectively, and share-based compensation expense is recognized (i) immediately at the grant date if no vesting conditions are required, or (ii) using the accelerated attribution method, net of estimated forfeitures, over the requisite service period. The fair value of restricted shares is determined with reference to the fair value of the underlying shares. At each date of measurement, the Company reviews internal and external sources of information to assist in the estimation of various attributes to determine the fair value of the share-based awards granted by the Company, including but not limited to the fair value of the Company ordinary shares, expected life, expected volatility and expected forfeiture rates. The Company is required to consider many factors and make certain assumptions during this assessment. If any of the assumptions used to determine the fair value of the share-based awards changes significantly, share-based compensation expense may differ materially in the future from that recorded in the current reporting period. Moreover, the estimates of fair value of the awards are not intended to predict actual future events or the value that ultimately will be realized by grantees who receive share-based awards, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by the Company for accounting purposes.
Value added tax	Value added tax The Company is subject to value added tax (“VAT”) and related surcharges on the revenues earned for both sales of products and rendering of services in the PRC. The applicable rate of value added tax is 6% on services and 13% on sales of products. The related surcharges for revenues derived from provision medical courses are deducted from gross receipts to arrive at net revenues.
Income taxes	Income taxes The Company accounts for income taxes in accordance with the U.S. GAAP for income taxes. Under the asset and liability method as required by this accounting standard, the recognition of deferred income tax liabilities and assets for the expected future tax consequences of temporary differences between the income tax basis and financial reporting basis of assets and liabilities. Provision for income taxes consists of taxes currently due plus deferred taxes. The charge for taxation is based on the results for the year as adjusted for items which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax basis. Deferred tax assets are recognized to the extent that it is more likely than not these items will be utilized against taxable income in the future. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities. An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. As of December 31, 2022, income tax returns for the tax years ended December 31, 2017 through December 31, 2021 remain open for statutory examination.
(Loss) earnings per share	(Loss) earnings per share Basic (loss) earnings per ordinary share is computed by dividing net (loss) income attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding during the period. Diluted (loss) earnings per share is computed by dividing net (loss) income attributable to ordinary shareholders by the sum of the weighted average number of ordinary share outstanding and of potential ordinary share (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted earnings per share.
Comprehensive (loss) income	Comprehensive (loss) income A Comprehensive (loss) income includes net (loss) income and other comprehensive (loss) income arising from foreign currency adjustments. Comprehensive (loss) income is reported in the consolidated statements of operations and comprehensive (loss) income.
Commitments and contingencies	Commitments and contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. In accordance with ASC No. 450-20, “Loss Contingencies”, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.
Operating lease	Operating lease The Company leases its offices which are classified as operating leases in accordance with Topic 842. Under Topic 842, lessees are required to recognize the following for all leases (with the exception of short-term leases) on the commencement date: (i) lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. At the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. No impairment for right-of-use lease assets as of December 31, 2022 and 2021.
Segment reporting	Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (the “CODM”), which is comprised of certain members of the Company’s management team. The Company’s organizational structure is based on a number of factors that the CODM uses to evaluate, view and run its business operations which include, but not limited to, customer base, homogeneity of service and technology. The Group’s operating segments are based on such organizational structure and information reviewed by the Company’s CODM to evaluate the operating segment results. Based on management’s assessment, the Company has determined that it has two operating segments: (i) provision of training and education services and assistance in patient-aid projects (collectively “MDMOOC services”). (ii) sales of patented drugs.
Reclassification	Reclassification Certain items in the financial statements of comparative period have been reclassified to conform to the financial statements for the current period. The reclassification has no impact on the total assets and total liabilities as of December 31, 2022 or on the statements of operations for the year ended December 31, 2022.
Recently issued accounting pronouncements	Recently issued accounting pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses Measurement of Credit Losses on Financial Instruments The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material impact on its the consolidated financial position, statements of operations and cash flows.
Significant risks and uncertainties	Significant risks and uncertainties 1) Credit risk Assets that potentially subject the Company to significant concentration of credit risk primarily consist of cash and cash equivalents. The maximum exposure of such assets to credit risk is their carrying amount as at the balance sheet dates. As of December 31, 2022, the Company held cash and cash equivalents of $11,520,453, among which were $4,700,379 was deposited in financial institutions located in Mainland China, and each bank account is insured by the government authority with the maximum limit of RMB 500,000 (equivalent to approximately $72,500). The Company also held cash of $4,709,310 deposited in the financial institutions in the United States, and each bank account is insured with the maximum limit of $250,000 by Federal Deposit Insurance Corporation (“FDIC”) insurance. In addition, the Company maintains certain bank accounts in Japan with cash balance of $1,538,404, which are not insured by FDIC insurance or other insurance. To limit exposure to credit risk relating to deposits, the Company primarily place cash and cash equivalent deposits with large financial institutions which management believes are of high credit quality and the Company also continually monitors their credit worthiness. The Company’s operations are carried out in China. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC as well as by the general state of the PRC’s economy. In addition, the Company’s business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, rates and methods of taxation among other factors. 2) Foreign currency risk Substantially all of the Company’s operating activities and the Company’s assets and liabilities are denominated in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the Peoples’ Bank of China (“PBOC”) or other authorized financial institutions at exchange rates quoted by PBOC. Approval of foreign currency payments by the PBOC or other regulatory institutions requires submitting a payment application form together with suppliers’ invoices and signed contracts. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. 3) Other risk The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, such as the COVID-19 outbreak and spread, management is currently evaluating the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and results of its operations, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Organization and Principal Ac_2

Organization and Principal Activities (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of financial statements of zhongchao shanghai	Name Background Ownership Zhongchao Group Inc. (“Zhongchao BVI”) ● A BVI company 100% owned by Zhongchao Cayman ● Incorporated on April 23, 2019 ● A holding company Zhongchao USA LLC (“Zhongchao USA”) ● A United States company 100% owned by Zhongchao Cayman ● Incorporated on 3 September, 2020 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed). Zhongchao Japan (“Zhongchao Japan”) ● A Japan company 100% owned by Zhongchao USA since December 2021. Before December 2021, 10% owned by Zhongchao USA and 90% owned by Mr. Weiguang Yang ● Incorporated on 1 October, 2020 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed). Zhongchao Group Limited (“Zhongchao HK”) ● A Hong Kong company 100% owned by Zhongchao BVI ● Incorporated on May 14, 2019 ● A holding company Beijing Zhongchao Zhongxing Technology Limited (“Zhongchao WFOE”) ● A PRC company and deemed a wholly foreign owned enterprise 100% owned by Zhongchao HK ● Incorporated on May 29, 2019 ● A holding company Zhongchao Shanghai ● A PRC limited liability company VIE of Beijing Zhongchao Zhongxing Technology Limited ● Incorporated on August 17, 2012 ● Engaged in technology development, technology transfer, and technical services in the field of medical technology, technical consulting in the field of network technology, and medical information consulting Shanghai Maidemu Cultural Communication Corp. (“Shanghai Maidemu”) ● A PRC limited liability company 100% owned by Zhongchao Shanghai ● Incorporated on March 12, 2015 ● Planning for cultural and artistic exchanges, designing, producing, acting for and publishing various kinds of advertisements, and medical consultation (no medical diagnosis and treatment activities allowed). Shanghai Huijing Information Technology Co., Ltd., (“Shanghai Huijing”) ● A PRC limited liability company 100% owned by Shanghai Maidemu ● Incorporated on September 28, 2016 ● Engaged in technology development, transfer, service and consulting in the fields of computer technology, graphic designing, website page designing, planning cultural and artistic exchanges. Shanghai Zhongxun Medical Technology Co., Ltd. (“Shanghai Zhongxun”) ● A PRC limited liability company 100% owned by Zhongchao Shanghai ● Incorporated on May 27, 2017 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed). Shanghai Zhongxin Medical Technology Co., Ltd (“Shanghai Zhongxin”) ● A PRC limited liability company 93.33% owned by Shanghai Zhongxun* ● Incorporated on October 10, 2018 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Beijing Zhongchao Boya Medical Technology Co., Ltd. (“Beijing Boya”) ● A PRC limited liability company 70% owned by Zhongchao Shanghai, and 30% owned by Mr. Zhengbo Ma on behalf of Zhongchao Shangha before December 8, 2021, and 30% owned by Shanghai Lingzhong Enterprise Management LLP on behalf of Zhongchao Shanghai after December 8, 2021 ● Incorporated on April 27, 2020 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Hainan Zhongteng Medical Technology Co., Ltd. (“Hainan Zhongteng”) ● A PRC limited liability company 100% owned by Beijing Boya ● Incorporated on July 16, 2021 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Zhixun Internet Hospital (Liaoning) Co., Ltd. (“Liaoning Zhixun”) ● A PRC limited liability company 100% owned by Beijing Boya ● Incorporated on July 6, 2020 ● Engaged in online hospital services, medical services, elderly nursing services, remote healthcare management services, healthcare consulting services, sales of medical appliances and other medical products. Shanghai Xinyuan Human Resources Co., Ltd. (“Shanghai Xinyuan”) ● A PRC limited liability company 100% owned by Shanghai Zhongxin ● Incorporated on January 13, 2021 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Hainan Muxin Medical Technology Co., Ltd. (“Hainan Muxin”) ● A PRC limited liability company 100% owned by Shanghai Zhongxin ● Incorporated on July 21, 2021 ● Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating. Ningxia Zhongxin Internet Hospital Co., Ltd. (“Ningxia Zhongxin”) ● A PRC limited liability company 100% owned by Shanghai Zhongxin ● Incorporated on May 18, 2021 and cancelled on September 1, 2022 ● Engaged in online hospital operation, provide online medical service, online consultation, prescription information services, and medication retails. Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Chongqing Xinjiang”) ● A PRC limited liability company 100% owned by Shanghai Zhongxun ● Incorporated on January 18, 2022 ● Engaged in trading of patented drugs Beijing Yisuizhen Technology Co., Ltd. (“Beijing Yisuizhen”) ● A PRC limited liability company 100% owned by Hainan Muxin ● Incorporated on November 8, 2021 ● Acquired by the Company on August 31, 2022 ● Provision of online platform for communication between hospitals and patients West Angel (Beijing) Health Technology Co., Ltd. (“West Angel”) ● A PRC limited liability company 60% owned by Beijing Yisuizhen ● Incorporated on July 1, 2003 ● Acquired by the Company on August 31, 2022 ● Provision of online platform for communication between hospitals and patients
Schedule of financial statements is reconciled	December 31, December 31, Number of Class A Ordinary Shares legally issued and outstanding 19,181,355 18,103,355 Class A Ordinary Shares committed to be issued to HF Capital 1,350,068 1,350,068 Number of Class A Ordinary Shares outstanding and issued presented on the financial statements 20,531,423 19,453,423

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of exchange rates	December 31, December 31, Balance sheet items, except for equity accounts 6.8972 6.3726 For the Years Ended 2022 2021 2020 Items in the statements of operations and comprehensive (loss) income, and statements of cash flows 6.7290 6.4508 6.9020
Schedule of property and equipment	Land and buildings 7 - 21 years Office equipment 3 years Vehicle 4 years Leasehold improvements 5 years
Schedule of amortized over their estimated useful lives	Trademarks 10 years License 10 years Software 3 - 10 years
Schedule of disaggregation of our revenue	For the Years Ended 2022 2021 2020 Medical training and education services $ 6,604,487 $ 8,754,120 $ 10,543,852 Patient management services in patient-aid projects 6,288,602 7,343,343 7,445,936 Sales of patented drugs 1,216,096 - - Other revenues 42,331 199,307 - Total $ 14,151,516 $ 16,296,770 $ 17,989,788

Variable Interest Entities an_2

Variable Interest Entities and Other Consolidation Matters (Tables)	12 Months Ended
	Dec. 31, 2022
Variable Interest Entities and Other Consolidation Matters [Member]
Schedule of consolidated financial statements	December 31, December 31, ASSETS Cash and cash equivalents $ 4,500,379 $ 7,117,728 Accounts receivable 6,772,988 9,218,883 Inventories 189,106 - Other current assets 1,840,182 2,029,794 Investment in a limited partnership and an equity investee 1,179,300 1,993,285 Property and equipment, net 3,111,717 3,168,441 Goodwill 5,767,504 - Right of use assets 1,666,777 205,824 Deferred tax assets 1,800,493 2,025,043 Other noncurrent assets 1,456,322 414,105 Total Assets $ 28,284,768 $ 26,173,103 LIABILITIES Advances from customers $ 395,263 $ 7,432 Income tax payable 2,292,765 2,478,273 Operating lease liabilities, current and non-current 1,702,478 201,559 Due to Zhongchao Inc.* 762,962 599,347 Other current liabilities 992,558 1,011,371 Deferred tax liabilities 208,200 - Total Liabilities $ 6,354,226 $ 4,297,982 For the years ended December 31, 2022 2021 2020 Revenues $ 14,151,516 $ 16,096,769 $ 17,989,788 (Loss) Income from Operations $ (1,716,154 ) $ 418,235 $ 4,525,855 Net (Loss) Income $ (1,427,296 ) $ 838,838 $ 4,484,029 * The balances due from/to Zhongchao Inc., are eliminated on consolidation.

Acquisition of Beijing Yisuiz_2

Acquisition of Beijing Yisuizhen and its Subsidiary (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Schedule of allocation of the purchase price as of the date of acquisition	Net assets deficit assumed (i) $ (60,092 ) Software acquired in business combination (ii) 1,000,406 Goodwill 5,767,504 Deferred tax liabilities (234,225 ) Non-controlling interest (iii) (2,585,087 ) Foreign currency adjustments 120,261 $ 4,008,767 Total purchase price is comprised of Cash consideration $ 3,055,432 Fair value of previously held equity interests (iv) 708,129 Fair value of 6.67% equity interest in Zhongxin (v) 393,816 Less: cash from transfer of fair value of 6.67% equity interest in Zhongxin (v) (148,610 ) $ 4,008,767 (i) Net asset deficit assumed primarily included other current liabilities for operating expenses. (ii) Software acquired in the business combination had estimated useful life of 3 years. (iii) Fair value of the noncontrolling interests was estimated with reference to the market price per share as of the acquisition date. (iv) A gain of $850 in relation to the revaluation of the previously held equity interests was recorded in other income, net in the consolidated statements of operations and comprehensive (loss) income for the year ended December 31, 2022. The fair value of the previously held equity interests approximated the cost of investments as Beijing Yisuizhen has not commenced operations since its setup. (v) In exchange for the equity interest in Beijing Yisuizhen and West Angel, the Company also granted 6.67% equity interest in Shanghai Zhongxin, with fair value of $393,816 (RMB 2,713,000), to four shareholders of West Angel at cash consideration of $148,610 (RMB 1,000,000). The Company engaged a third party valuation team to estimate the fair value of equity interest of Shanghai Zhongxin. As of December 31, 2022, the four shareholders paid the cash consideration to Mr. Yang, the Chief Executive Officer of the Company. The Company recorded the outstanding balance in the account of due from related parties (Note 16).

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Other Current Assets [Abstract]
Schedule of Other current assets	December 31, December 31, Due from a third party (i) $ 205,726 $ - Office rental deposit 128,194 203,896 Interest receivable 88,720 78,950 Prepaid rental fees 803 45,607 Others 69,597 47,256 $ 493,040 $ 375,709 (i) During the year ended December 31, 2022, the Company sold one of its properties to a third party at cash consideration of $1,323,308 (Note 8), among which the third party paid $1,112,440. The Company recorded the remaining balance as “due from a third party” in the account of other current assets.

Loans Receivable (Tables)

Loans Receivable (Tables)	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Schedule of loans receivable	December 31, December 31, Borrower A $ - $ 266,767 Borrower B - 199,893 Borrower C - 404,008 Borrower D 1,590,000 1,590,000 Borrower E 250,000 200,000 $ 1,840,000 $ 2,660,668

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	December 31, December 31, Land and buildings $ 4,105,956 $ 4,063,587 Office equipment 79,082 460,525 Vehicle 32,535 35,213 Leasehold improvements 53,253 - Less: accumulated depreciation (379,879 ) (636,239 ) $ 3,890,947 $ 3,923,086

Prepayments for Lease of Land (

Prepayments for Lease of Land (Tables)	12 Months Ended
	Dec. 31, 2022
Prepayments for Lease of Land [Abstract]
Schedule of prepayments for lease of land	December 31, December 31, Prepayments for lease of land $ 401,031 $ 434,045 Less: accumulated amortization (96,244 ) (80,698 ) $ 304,787 $ 353,347

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	December 31, December 31, Software $ 1,041,872 $ 44,880 Trademark and license 11,133 12,050 Less: accumulated amortization (140,951 ) (26,671 ) $ 912,054 $ 30,259
Schedule of amortization of intangible assets	December 31, For the year ended December 31, 2023 $ 338,636 For the year ended December 31, 2024 338,636 For the year ended December 31, 2025 227,492 For the year ended December 31, 2026 5,105 For the year ended December 31, 2027 2,185 $ 912,054

Investments in Equity Method _2

Investments in Equity Method Investees (Tables)	12 Months Ended
	Dec. 31, 2022
Investment Company, Financial Highlights [Abstract]
Schedule of investments in equity investments	December 31, December 31, Ningbo Meishan Xinaishan Equity Investment Limited Partnership (“limited partnership”) (a) $ 1,179,300 $ 1,276,466 Beijing Yisuizhen (b) - 716,819 $ 1,179,300 $ 1,993,285 (a) On November 5, 2020, the Company entered into a five-year partnership agreement to invest $1,217,039, for 28% partnership interest in the limited partnership. The funds raised by the limited partnership are invested in one PRC private company engaged in immunotherapy. For the years ended December 31, 2022, 2021 and 2020, equity investment loss of $80, $13,758 and $25,622 have been recorded in other income, net for the Company’s share of the operating loss of the limited partnership. As of December 31, 2022 and 2021, no significant impairment indicators have been noted in connection with the investment. (b) On November 8, 2021, the Company newly set up Beijing Yisuizhen with other investors and acquired 47% equity interest at cash consideration of $708,129. In August 2022, the Company, through Hainan Muxin, acquired additional 53% equity interest in Beijing Yisuizhen, which was consolidated in the Company’s consolidated financial statements. Beijing Yisuizhen has not commenced operations. In addition, the Company did not note significant impairment indicators in connection with the investment.

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Other Current Assets [Abstract]
Schedule of accrued expenses and other current liabilities	December 31, December 31, Other tax payable $ 379,712 $ 616,356 Accrued payroll 296,866 301,260 Customer deposits payable 83,367 - Other current liabilities 95,595 57,185 $ 855,540 $ 974,801
Schedule of other tax payables	December 31, December 31, Value added tax payable $ 354,794 $ 579,516 Local taxes payable 24,918 36,840 $ 379,712 $ 616,356

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of components of (loss) profit before income tax benefits (expenses) are summarized	For the Years Ended 2022 2021 2020 PRC $ (1,243,361 ) $ 631,917 $ 4,976,484 Non-PRC (1,306,645 ) (742,670 ) (34,600 ) Total $ (2,550,006 ) $ (110,753 ) $ 4,941,884
Schedule of income tax expenses	For the Years Ended 2022 2021 2020 Current income tax expenses $ (138,188 ) $ (997,198 ) $ (543,211 ) Deferred income tax benefits (134,125 ) 1,346,616 58,424 Income tax benefits (expenses) $ (272,313 ) $ 349,418 $ (484,787 )
Schedule of reconciliation of statutory tax rate to effective tax rate	For the Years Ended 2022 2021 2020 PRC statutory income tax rate 25 % 25 % 25 % Effect of different income tax rates in other jurisdictions (2.11 )% (34.11 )% 0 % Effect of preferential tax benefits 12.72 % 167.36 % (13.96 )% Effect of non-deductible expenses (1.22 )% (54.84 )% 0.35 % Effect of research and development credits 3.06 % 104.55 % (1.47 )% Effect of deferred tax rate change (34.22 )% 107.53 % 0 % Effect of changes in valuation allowance (13.91 )% 0 % 0 % Effective tax rate (10.68 )% 315.49 % 9.81 %
Schedule of deferred tax assets	December 31, December 31, Deferred tax assets: Excess advertising expense $ 842,295 $ 911,799 Deferred Intangible assets amortization 25,790 33,590 Net operating loss carrying forward 1,052,209 1,079,962 Share-based compensation 178,764 156,928 Doubtful allowance against accounts receivable 51,817 - Changes in fair value of short-term investments 50,502 - Downward adjustments in investments in an equity security 13,733 - Lease liabilities 71,024 31,615 Less: Deferred tax liability - Right of use assets (81,910 ) (37,184 ) Less: Valuation allowance on deferred tax assets (339,495 ) - Deferred tax assets, net $ 1,864,729 $ 2,176,710 Deferred tax liability Software acquired in business combination 208,200 - $ 208,200 $ -

(Loss) Earnings Per Share (Tabl

(Loss) Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of basic and diluted loss per ordinary share	For the Years Ended 2022 2021 2020 Net (Loss) Income Attributable to Zhongchao Inc.’s shareholders $ (2,940,891 ) $ 238,665 $ 4,458,380 Weighted average number of ordinary share outstanding Basic and Diluted 25,997,757 24,938,513 24,425,637 (Loss) Earnings per share Basic and Diluted $ (0.113 ) $ 0.010 $ 0.183

Related Party Transactions an_2

Related Party Transactions and Balances (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of relationships with related parties	Name Relationship with the Company Yang Weiguang Chairman of the Board, Chief Executive Officer Beijing Ougaini Trading Co., Ltd (“Beijing Ougaini”) Controlled by an immediate family member of Mr. Yang Weiguang Beijing Yisuizhen The Company owned 47% and 100% equity interest before and after August 17, 2022, respectively
Schedule of relationships with related parties	For the Years Ended 2022 2021 2020 Beijing Ougaini $ 19,696 $ - $ -
Schedule of the balances with related parties	December 31, December 31, Prepayments Beijing Ougaini $ 115,989 $ - Due from related parties Yang Weiguang (i) 226,178 - Beijing Yisuizhen (ii) - 392,305 $ 226,178 $ 392,305 (i) As of December 31, 2022, the Company had a balance of $226,178 due from Mr. Yang Weiguang. The balance was comprised of the following: - A balance of $144,986 arising from transfer of 6.67% equity interest of Shanghai Zhongxin to four former shareholders of West Angel, who paid consideration to Mr. Yang. (Note 4) - A balance of $81,192 as tuition paid on behalf of to Mr. Yang. As of the date of this report, Mr. Yang has repaid the above outstanding balances to the Company. (ii) As of December 31, 2021, the Company had a balance of $392,305 due from Beijing Yisuizhen, over which the Company owned 47% equity interest before August 17, 2022. The balance was a loan to the newly set up equity investee to support its working capital. The outstanding balance was repaid by Beijing Yisuizhen before business combination with the Company.

Share Based Compensation (Table

Share Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of unvested restricted share units	Number of Weighted- Unvested at December 31, 2020 427,076 $ 2.54 Granted 18,000 $ 1.64 Vested (18,000 ) $ 1.77 Unvested at December 31, 2021 427,076 $ 2.53 Granted 18,000 $ 1.16 Vested (137,880 ) $ 2.37 Unvested at December 31, 2022 307,196 $ 2.52
Schedule of share based compensation operating expenses	For the Years Ended 2022 2021 2020 Selling and marketing expenses $ 61,607 $ 111,997 $ 93,439 General and administrative expenses 99,170 99,826 74,911 Total share-based compensation expenses $ 160,777 $ 211,823 $ 168,350

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of presents major accounts of statements of operations	MDMOOC Services Sales of patented drugs Total Revenues $ 12,935,420 $ 1,216,096 $ 14,151,516 Cost of revenues $ (7,166,871 ) $ (627,981 ) $ (7,794,852 ) Total operating expenses $ (9,153,373 ) $ (157,753 ) $ (9,311,126 ) Net Loss $ (2,409,212 ) $ (413,107 ) $ (2,822,319 )
Schedule of geographical segments	December 31, December 31, Total assets MDMOOC services $ 37,183,491 $ 36,267,420 Sales of patented drugs 1,430,854 - $ 38,614,345 $ 36,267,420

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of operating lease related assets and liabilities	December 31, December 31, Rights of use lease assets $ 1,666,777 $ 205,824 Operating lease liabilities, current 480,633 88,968 Operating lease liabilities, noncurrent 1,221,845 112,591 Total operating lease liabilities $ 1,702,478 $ 201,559
Schedule of maturities of lease liabilities	2023 $ 550,915 2024 324,647 2025 317,927 2026 317,980 2027 and thereafter 397,475 Total lease payments 1,908,944 Less: imputed interest (206,466 ) Present value of lease liabilities $ 1,702,478

Condensed financial informati_2

Condensed financial information of the parent company (Tables)	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Disclosure [Abstract]
Schedule of parent company balance sheet	December 31, December 31, ASSETS Cash and cash equivalents $ 4,110,216 $ 3,758,618 Due from subsidiaries 9,423,617 7,785,162 Investment in subsidiaries, VIE and VIE’s subsidiaries 16,906,213 21,022,642 Total Assets $ 30,440,046 $ 32,566,422 LIABILITIES AND EQUITY Total Liabilities $ - $ - Commitments and Contingencies Shareholders’ Equity Class A Ordinary Share (par value $0.0001 per share, 450,000,000 shares authorized; 20,531,423 and 19,453,423 shares issued and outstanding at December 31, 2022 and 2021, respectively) 2,054 1,946 Class B Ordinary Share (par value $0.0001 per share, 50,000,000 shares authorized; 5,497,715 and 5,497,715 shares issued and outstanding at December 31, 2022 and 2021, respectively) 550 550 Additional paid-in capital 24,998,388 22,986,975 Retained earnings 5,439,054 8,379,945 Accumulated comprehensive income - 1,197,006 Total Shareholders’ Equity 30,440,046 32,566,422 Total Liabilities and Shareholders’ Equity $ 30,440,046 $ 32,566,422
Schedule of parent company statements of operations and comprehensive (loss) Income	For the Years Ended 2022 2021 2020 Equity in (loss) gain of subsidiaries $ (2,919,423 ) $ 266,775 $ 4,470,613 General and administrative expenses (23,193 ) (32,273 ) (12,233 ) Interest income 1,725 4,163 - Net (Loss) Income $ (2,940,891 ) 238,665 4,458,380
Schedule of parent company statements of cash flows	For the Years Ended 2022 2021 2020 Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities $ 139,309 $ 3,737 $ (700,873 ) Cash Flows from Investing Activities: Loans repaid from (made to) VIE and its subsidiaries (1,638,455 ) (3,400,000 ) (3,690,000 ) Net Cash Used in Investing Activities (1,638,455 ) (3,400,000 ) (3,690,000 ) Cash Flows from Financing Activities: Proceeds from issuance of common stocks in connection with initial public offering, net off issuance cost - - 11,497,654 Proceeds from issuance of common stocks in connection with direct offering, net off issuance cost 1,850,744 - - Net Cash Provided by Financing Activities 1,850,744 - 11,497,654 Net increase (decrease) in cash and cash equivalents 351,598 (3,396,263 ) 7,106,781 Cash and cash equivalents at beginning of year 3,758,618 7,154,881 48,100 Cash and cash equivalents at end of year $ 4,110,216 $ 3,758,618 $ 7,154,881

Organization and Principal Ac_3

Organization and Principal Activities (Details) ¥ in Millions, $ in Millions		12 Months Ended
	Aug. 14, 2019	Dec. 31, 2022 shares	Dec. 31, 2021 shares	Sep. 10, 2021	Nov. 30, 2020	Aug. 01, 2020	Dec. 02, 2019 USD ($)	Dec. 02, 2019 CNY (¥)	Aug. 15, 2019 shares
Organization and Principal Activities (Details) [Line Items]
Shares issued (in Shares)									1,350,068
Purchased remaining shares (in Shares)									675,000
Percentage of economic beneficial interest		5.19%
Ownership voting percentage		1.31%
Amount of paid-in capital of HF capital							$ 2.9	¥ 20
Initial equity interest pledge agreement term	20 years
Service fees percentage	100%
Shanghai Zhongxun [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage		93.33%	100%		51%
Mr. Weiguang Yang [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage		6.67%			19%
Beijing Zhongchao Yixin Management Consulting Partnership [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage					20%
LLP (“Zhongchao Yixin”), and Beijing Zhongren Yixin Management Consulting [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage					10%
West Angel [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage		60%
Zhongchao Shanghai [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage				100%					6.25%
Mr.Yang [Member]
Organization and Principal Activities (Details) [Line Items]
Equity interest percentage						76.40%
Class A Ordinary Shares [Member]
Organization and Principal Activities (Details) [Line Items]
Capital to purchase shares (in Shares)		1,350,068
Ordinary shares would not be issued (in Shares)		1,350,068	1,350,068
Ordinary shares outstanding (in Shares)		1,350,068	1,350,068
Zhongchao Shanghai [Member]
Organization and Principal Activities (Details) [Line Items]
Shares issued (in Shares)									675,068

Organization and Principal Ac_4

Organization and Principal Activities (Details) - Schedule of financial statements of Zhongchao Shanghai	12 Months Ended
	Dec. 31, 2022
Zhongchao Group Inc. ("Zhongchao BVI") [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A BVI company
Ownership	100% owned by Zhongchao Cayman
Zhongchao Group Inc. (“Zhongchao BVI”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on April 23, 2019
Zhongchao Group Inc. (“Zhongchao BVI”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A holding company
Zhongchao USA LLC (“Zhongchao USA”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A United States company
Ownership	100% owned by Zhongchao Cayman
Zhongchao USA LLC (“Zhongchao USA”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on 3 September, 2020
Zhongchao USA LLC (“Zhongchao USA”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed).
Zhongchao Japan (“Zhongchao Japan”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A Japan company
Ownership	100% owned by Zhongchao USA since December 2021. Before December 2021, 10% owned by Zhongchao USA   and 90% owned by Mr. Weiguang Yang
Zhongchao Japan (“Zhongchao Japan”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on 1 October, 2020
Zhongchao Japan (“Zhongchao Japan”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed).
Zhongchao Group Limited ("Zhongchao HK") [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A Hong Kong company
Ownership	100% owned by Zhongchao BVI
Zhongchao Group Limited (“Zhongchao HK”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on May 14, 2019
Zhongchao Group Limited (“Zhongchao HK”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A holding company
Beijing Zhongchao Zhongxing Technology Limited ("Zhongchao WFOE") [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC company and deemed a wholly foreign owned enterprise
Ownership	100% owned by Zhongchao HK
Beijing Zhongchao Zhongxing Technology Limited (“Zhongchao WFOE”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on May 29, 2019
Beijing Zhongchao Zhongxing Technology Limited (“Zhongchao WFOE”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A holding company
Zhongchao Shanghai [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	VIE of Beijing Zhongchao Zhongxing Technology Limited
Zhongchao Shanghai One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on August 17, 2012
Zhongchao Shanghai Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, technology transfer, and technical services in the field of medical technology, technical consulting in the field of network technology, and medical information consulting
Shanghai Maidemu Cultural Communication Corp. ("Shanghai Maidemu") [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Zhongchao Shanghai
Shanghai Maidemu Cultural Communication Corp. (“Shanghai Maidemu”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on March 12, 2015
Shanghai Maidemu Cultural Communication Corp. (“Shanghai Maidemu”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Planning for cultural and artistic exchanges, designing, producing, acting for and publishing various kinds of advertisements, and medical consultation (no medical diagnosis and treatment activities allowed).
Shanghai Huijing Information Technology Co., Ltd., ("Shanghai Huijing") [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Shanghai Maidemu
Shanghai Huijing Information Technology Co., Ltd., (“Shanghai Huijing”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on September 28, 2016
Shanghai Huijing Information Technology Co., Ltd., (“Shanghai Huijing”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of computer technology, graphic designing, website page designing, planning cultural and artistic exchanges.
Shanghai Zhongxun Medical Technology Co., Ltd. (“Shanghai Zhongxun”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Zhongchao Shanghai
Shanghai Zhongxun Medical Technology Co., Ltd. (“Shanghai Zhongxun”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on May 27, 2017
Shanghai Zhongxun Medical Technology Co., Ltd. (“Shanghai Zhongxun”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology (no medical diagnosis and treatment activities allowed).
Shanghai Zhongxin Medical Technology Co., Ltd (“Shanghai Zhongxin”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	93.33% owned by Shanghai Zhongxun*
Shanghai Zhongxin Medical Technology Co., Ltd (“Shanghai Zhongxin”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on October 10, 2018
Shanghai Zhongxin Medical Technology Co., Ltd (“Shanghai Zhongxin”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating.
Beijing Zhongchao Boya Medical Technology Co., Ltd. (“Beijing Boya”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	70% owned by Zhongchao Shanghai, and 30% owned by Mr. Zhengbo Ma on behalf of Zhongchao Shangha before December 8, 2021, and 30% owned by Shanghai Lingzhong Enterprise Management LLP on behalf of Zhongchao Shanghai after December 8, 2021
Beijing Zhongchao Boya Medical Technology Co., Ltd. (“Beijing Boya”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on April 27, 2020
Beijing Zhongchao Boya Medical Technology Co., Ltd. (“Beijing Boya”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating.
Hainan Zhongteng Medical Technology Co., Ltd. (“Hainan Zhongteng”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Beijing Boya
Hainan Zhongteng Medical Technology Co., Ltd. (“Hainan Zhongteng”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on July 16, 2021
Hainan Zhongteng Medical Technology Co., Ltd. (“Hainan Zhongteng”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating.
Zhixun Internet Hospital (Liaoning) Co., Ltd. (“Liaoning Zhixun”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Beijing Boya
Zhixun Internet Hospital (Liaoning) Co., Ltd. (“Liaoning Zhixun”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on July 6, 2020
Zhixun Internet Hospital (Liaoning) Co., Ltd. (“Liaoning Zhixun”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in online hospital services, medical services, elderly nursing services, remote healthcare management services, healthcare consulting services, sales of medical appliances and other medical products.
Shanghai Xinyuan Human Resources Co., Ltd. (“Shanghai Xinyuan”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Shanghai Zhongxin
Shanghai Xinyuan Human Resources Co., Ltd. (“Shanghai Xinyuan”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on January 13, 2021
Shanghai Xinyuan Human Resources Co., Ltd. (“Shanghai Xinyuan”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating.
Hainan Muxin Medical Technology Co., Ltd. (“Hainan Muxin”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Shanghai Zhongxin
Hainan Muxin Medical Technology Co., Ltd. (“Hainan Muxin”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on July 21, 2021
Hainan Muxin Medical Technology Co., Ltd. (“Hainan Muxin”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in technology development, transfer, service and consulting in the fields of medical technology and computer technology, market information consulting and investigating.
Ningxia Zhongxin Internet Hospital Co., Ltd. (“Ningxia Zhongxin”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Shanghai Zhongxin
Ningxia Zhongxin Internet Hospital Co., Ltd. (“Ningxia Zhongxin”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on May 18, 2021 and cancelled on September 1, 2022
Ningxia Zhongxin Internet Hospital Co., Ltd. (“Ningxia Zhongxin”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in online hospital operation, provide online medical service, online consultation, prescription information services, and medication retails.
Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Chongqing Xinjiang”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Shanghai Zhongxun
Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Chongqing Xinjiang”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on January 18, 2022
Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Chongqing Xinjiang”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Engaged in trading of patented drugs
Beijing Yisuizhen Technology Co., Ltd. (“Beijing Yisuizhen”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	100% owned by Hainan Muxin
Beijing Yisuizhen Technology Co., Ltd. (“Beijing Yisuizhen”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on November 8, 2021
Beijing Yisuizhen Technology Co., Ltd. (“Beijing Yisuizhen”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Acquired by the Company on August 31, 2022
Beijing Yisuizhen Technology Co., Ltd. (“Beijing Yisuizhen”) Three [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Provision of online platform for communication between hospitals and patients
West Angel (Beijing) Health Technology Co., Ltd. (“West Angel”) [Member]
Condensed Financial Statements, Captions [Line Items]
Background	A PRC limited liability company
Ownership	60% owned by Beijing Yisuizhen
West Angel (Beijing) Health Technology Co., Ltd. (“West Angel”) One [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Incorporated on July 1, 2003
West Angel (Beijing) Health Technology Co., Ltd. (“West Angel”) Two [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Acquired by the Company on August 31, 2022
West Angel (Beijing) Health Technology Co., Ltd. (“West Angel”) Three [Member]
Condensed Financial Statements, Captions [Line Items]
Background	Provision of online platform for communication between hospitals and patients

Organization and Principal Ac_5

Organization and Principal Activities (Details) - Schedule of financial statements is reconciled - Class A Ordinary Shares [Member] - shares	Dec. 31, 2022	Dec. 31, 2021
Organization and Principal Activities (Details) - Schedule of financial statements is reconciled [Line Items]
Number of Class A Ordinary Shares legally issued and outstanding	19,181,355	18,103,355
Class A Ordinary Shares committed to be issued to HF Capital	1,350,068	1,350,068
Number of Class A Ordinary Shares outstanding and issued presented on the financial statements	20,531,423	19,453,423

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 CNY (¥)
Summary of Significant Accounting Policies (Details) [Line Items]
Minority equity interest	40%
Accounts receivable	$ 753,447	$ 1,449,827	$ 336,367
Written off	543,315	1,449,827	$ 336,367
Doubtful accounts	$ 207,269
Depreciation	5%			5%
Amortization period	1 year
Other revenues percentage	0.30%	1.20%	0%
Employee benefits	$ 817,345	$ 804,730	$ 310,637
Research and development costs	411,524	758,878	816,553
Advertising expenses	$ 989,900	$ 2,204,233	$ 2,851,648
Value added tax	6%			6%
Sale of product	13%
Amount of tax benefit	50%
Cash and cash equivalents	$ 4,709,310
Deposited in financial institutions	4,700,379
Bank account	72,500			¥ 500,000
Federal deposit insurance corporation	250,000
Cash balance	$ 1,538,404
Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Minority equity interest	3%
Straight-line basis term	16 years			16 years
Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Minority equity interest	5%
Straight-line basis term	32 years			32 years
Credit Risk [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Cash and cash equivalents	$ 11,520,453
Zhongxin [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Minority equity interest	6.67%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of exchange rates	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of exchange rates [Abstract]
Balance sheet items, except for equity accounts	6.8972	6.3726
Items in the statements of operations and comprehensive (loss) income, and statements of cash flows	6.7290	6.4508	6.9020

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of property and equipment	12 Months Ended
	Dec. 31, 2022
Land and buildings [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment	7 years
Land and buildings [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment	21 years
Office equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment	3 years
Vehicle [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment	4 years
Leasehold improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of amortized over their estimated useful lives	12 Months Ended
	Dec. 31, 2022
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Amortized estimated useful lives	10 years
License [Member]
Finite-Lived Intangible Assets [Line Items]
Amortized estimated useful lives	10 years
Software [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortized estimated useful lives	3 years
Software [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortized estimated useful lives	10 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of our revenue - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of disaggregation of our revenue [Abstract]
Medical training and education services	$ 6,604,487	$ 8,754,120	$ 10,543,852
Patient management services in patient-aid projects	6,288,602	7,343,343	7,445,936
Sales of patented drugs	1,216,096
Other revenues	42,331	199,307
Total	$ 14,151,516	$ 16,296,770	$ 17,989,788

Variable Interest Entities an_3

Variable Interest Entities and Other Consolidation Matters (Details) - Schedule of consolidated financial statements - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents		$ 4,500,379	$ 7,117,728
Accounts receivable		6,772,988	9,218,883
Inventories		189,106
Other current assets		1,840,182	2,029,794
Investment in a limited partnership and an equity investee		1,179,300	1,993,285
Property and equipment, net		3,111,717	3,168,441
Goodwill		5,767,504
Right of use assets		1,666,777	205,824
Deferred tax assets		1,800,493	2,025,043
Other noncurrent assets		1,456,322	414,105
Total Assets		28,284,768	26,173,103
LIABILITIES
Advances from customers		395,263	7,432
Income tax payable		2,292,765	2,478,273
Operating lease liabilities, current and non-current		1,702,478	201,559
Due to Zhongchao Inc.	[1]	762,962	599,347
Other current liabilities		992,558	1,011,371
Deferred tax liabilities		208,200
Total Liabilities		6,354,226	4,297,982
Revenues		14,151,516	16,096,769	$ 17,989,788
(Loss) Income from Operations		(1,716,154)	418,235	4,525,855
Net (Loss) Income		$ (1,427,296)	$ 838,838	$ 4,484,029
[1] The balances due from/to Zhongchao Inc., are eliminated on consolidation.

Acquisition of Beijing Yisuiz_3

Acquisition of Beijing Yisuizhen and its Subsidiary (Details)	1 Months Ended					12 Months Ended
	Aug. 31, 2022 USD ($)	Aug. 31, 2022 CNY (¥)	Feb. 28, 2022 CNY (¥)	Nov. 30, 2021 USD ($)	Nov. 30, 2021 CNY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Dec. 31, 2022 CNY (¥)
Acquisition of Beijing Yisuizhen and its Subsidiary (Details) [Line Items]
Capital contribution				$ 708,129	¥ 4,568,000
Cash consideration	$ 3,100,000	¥ 20,600,000	¥ 25,000,000			$ 148,610	¥ 1,000,000
Share consideration percentage	6.67%	6.67%	6.67%
Estimated useful life						3 years	3 years
Equity interests (in Dollars)						$ 850
Granted percentage						6.67%	6.67%
Fair value amount						$ 393,816		¥ 2,713,000
Beijing Yisuizhen [Member]
Acquisition of Beijing Yisuizhen and its Subsidiary (Details) [Line Items]
Equity interest rate			60%	47%	47%
Beijing Yisuizhen and Beijing Yisuizhen [Member]
Acquisition of Beijing Yisuizhen and its Subsidiary (Details) [Line Items]
Equity interest rate	100%	100%

Acquisition of Beijing Yisuiz_4

Acquisition of Beijing Yisuizhen and its Subsidiary (Details) - Schedule of allocation of the purchase price as of the date of acquisition - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Schedule of Allocation Purchase Acquisition [Abstract]
Net assets deficit assumed	[1]	$ (60,092)
Software acquired in business combination	[2]	1,000,406
Goodwill		5,767,504
Deferred tax liabilities		(234,225)
Non-controlling interest	[3]	(2,585,087)
Foreign currency adjustments		120,261
Total		4,008,767
Total purchase price is comprised of
Cash consideration		3,055,432
Fair value of previously held equity interests	[4]	708,129
Fair value of 6.67% equity interest in Zhongxin	[5]	393,816
Less: cash from transfer of fair value of 6.67% equity interest in Zhongxin (v)	[5]	(148,610)
Total		$ 4,008,767
[1]Net asset deficit assumed primarily included other current liabilities for operating expenses.[2]Software acquired in the business combination had estimated useful life of 3 years.[3]Fair value of the noncontrolling interests was estimated with reference to the market price per share as of the acquisition date.[4]A gain of $850 in relation to the revaluation of the previously held equity interests was recorded in other income, net in the consolidated statements of operations and comprehensive (loss) income for the year ended December 31, 2022. The fair value of the previously held equity interests approximated the cost of investments as Beijing Yisuizhen has not commenced operations since its setup.[5]In exchange for the equity interest in Beijing Yisuizhen and West Angel, the Company also granted 6.67% equity interest in Shanghai Zhongxin, with fair value of $393,816 (RMB 2,713,000), to four shareholders of West Angel at cash consideration of $148,610 (RMB 1,000,000). The Company engaged a third party valuation team to estimate the fair value of equity interest of Shanghai Zhongxin. As of December 31, 2022, the four shareholders paid the cash consideration to Mr. Yang, the Chief Executive Officer of the Company. The Company recorded the outstanding balance in the account of due from related parties (Note 16).

Short-Term Investments (Details

Short-Term Investments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Short-term Investments [Abstract]
Loss on short-term investment	$ 240,489	$ 58,403	$ 10,331

Other Current Assets (Details)

Other Current Assets (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Other Current Assets [Abstract]
Cash consideration	$ 1,323,308
Third party paid	$ 1,112,440

Other Current Assets (Details)

Other Current Assets (Details) - Schedule of other current assets - USD ($)		Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Current Assets [Abstract]
Due from a third party	[1]	$ 205,726
Office rental deposit		128,194	203,896
Interest receivable		88,720	78,950
Prepaid rental fees		803	45,607
Others		69,597	47,256
Total		$ 493,040	$ 375,709
[1] During the year ended December 31, 2022, the Company sold one of its properties to a third party at cash consideration of $1,323,308 (Note 8), among which the third party paid $1,112,440. The Company recorded the remaining balance as “due from a third party” in the account of other current assets.

Loans Receivable (Details)

Loans Receivable (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 CNY (¥)
Loans Receivable (Details) [Line Items]
Total amount		$ 775,098	¥ 5,000,000
Collected amount	$ 150,000
Borrower A [Member]
Loans Receivable (Details) [Line Items]
Loans amount		1,038,631	6,700,000
Borrower B [Member]
Loans Receivable (Details) [Line Items]
Loans amount		197,470	1,273,840
Borrower C [Member]
Loans Receivable (Details) [Line Items]
Loans amount		399,110	¥ 2,574,580
Borrower D [Member]
Loans Receivable (Details) [Line Items]
Loans amount		1,890,000
Collected amount		300,000
Loans collected amount	1,590,000
Borrower E [Member]
Loans Receivable (Details) [Line Items]
Loans amount	200,000	$ 200,000
Loans collected amount	$ 250,000

Loans Receivable (Details) - Sc

Loans Receivable (Details) - Schedule of loans receivable - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Loans Receivable (Details) - Schedule of loans receivable [Line Items]
Total loans receivable	$ 1,840,000	$ 2,660,668
Borrower A [Member]
Loans Receivable (Details) - Schedule of loans receivable [Line Items]
Total loans receivable		266,767
Borrower B [Member]
Loans Receivable (Details) - Schedule of loans receivable [Line Items]
Total loans receivable		199,893
Borrower C [Member]
Loans Receivable (Details) - Schedule of loans receivable [Line Items]
Total loans receivable		404,008
Borrower D [Member]
Loans Receivable (Details) - Schedule of loans receivable [Line Items]
Total loans receivable	1,590,000	1,590,000
Borrower E [Member]
Loans Receivable (Details) - Schedule of loans receivable [Line Items]
Total loans receivable	$ 250,000	$ 200,000

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 241,842	$ 312,898	$ 176,111
Building with original amount				$ 1,397,317
Sale of property	$ 1,323,308

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (379,879)	$ (636,239)
Property, plant and equipment gross	3,890,947	3,923,086
Land and buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment net	4,105,956	4,063,587
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment net	79,082	460,525
Vehicle [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment net	32,535	35,213
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment net	$ 53,253

Prepayments for Lease of Land_2

Prepayments for Lease of Land (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Prepayments for Lease of Land [Abstract]
Amortization expenses	$ 22,226	$ 23,185	$ 21,670

Prepayments for Lease of Land_3

Prepayments for Lease of Land (Details) - Schedule of prepayments for lease of land - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Prepayments For Lease Of Land [Abstract]
Prepayments for lease of land	$ 401,031	$ 434,045
Less: accumulated amortization	(96,244)	(80,698)
Total	$ 304,787	$ 353,347

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 119,218	$ 5,525	$ 4,544

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details) - Schedule of intangible assets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Intangible assets, net	$ 912,054	$ 30,259
Less: accumulated amortization	(140,951)	(26,671)
Software [Member]
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Intangible assets, net	1,041,872	44,880
Trademark and License [Member]
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Intangible assets, net	$ 11,133	$ 12,050

Intangible Assets, Net (Detai_3

Intangible Assets, Net (Details) - Schedule of amortization of intangible assets	Dec. 31, 2022 USD ($)
Schedule of Amortization Of Intangible Assets [Abstract]
For the year ended December 31, 2023	$ 338,636
For the year ended December 31, 2024	338,636
For the year ended December 31, 2025	227,492
For the year ended December 31, 2026	5,105
For the year ended December 31, 2027	2,185
Total amortization	$ 912,054

Investments in Equity Method _3

Investments in Equity Method Investees (Details) - USD ($)		12 Months Ended
	Nov. 08, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2022	Nov. 05, 2020
Investments in Equity Method Investees (Details) [Line Items]
Investment amount						$ 1,217,039
Partnership interest percentage						28%
Investment loss		$ 80	$ 13,758	$ 25,622
Investors and acquired percentage	47%
Cash consideration	$ 708,129
Hainan Muxin [Member]
Investments in Equity Method Investees (Details) [Line Items]
Equity interest rate					53%

Investments in Equity Method _4

Investments in Equity Method Investees (Details) - Schedule of investments in equity investments - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Ningbo Meishan Xinaishan Equity Investment Limited Partnership (“limited partnership”)	[1]	$ 1,179,300	$ 1,276,466
Total		1,179,300	1,993,285
Beijing Yisuizhen [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Beijing Easy Clinic Technology Co., Ltd. (“Easy Clinic”)	[2]		$ 716,819
[1] On November 5, 2020, the Company entered into a five-year partnership agreement to invest $1,217,039, for 28% partnership interest in the limited partnership. The funds raised by the limited partnership are invested in one PRC private company engaged in immunotherapy. For the years ended December 31, 2022, 2021 and 2020, equity investment loss of $80, $13,758 and $25,622 have been recorded in other income, net for the Company’s share of the operating loss of the limited partnership. As of December 31, 2022 and 2021, no significant impairment indicators have been noted in connection with the investment.

Investment in an Equity Secur_2

Investment in an Equity Security (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investment amount		$ 150,000
Investee percentage		0.60%
Downward adjustments	$ 65,394

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Accrued Expenses And Other Current Liabilities [Abstract]
Other tax payable	$ 379,712	$ 616,356
Accrued payroll	296,866	301,260
Customer deposits payable	83,367
Other current liabilities	95,595	57,185
Accrued expenses and other current liabilities	$ 855,540	$ 974,801

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Details) - Schedule of other tax payables - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of Other Tax Payables [Abstract]
Value added tax payable	$ 354,794	$ 579,516
Local taxes payable	24,918	36,840
Other tax payables	$ 379,712	$ 616,356

Income Taxes (Details)

Income Taxes (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jan. 01, 2021	Sep. 30, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes (Details) [Line Items]
Applicable tax rate, description				The applicable tax rate for the first HKD$2 million of assessable profits is 8.25% and assessable profits above HKD$2 million will continue to be subject to the rate of 16.5% for corporations in Hong Kong, effective from the year of assessment 2018/2019. Before that, the applicable tax rate was 16.5% for corporations in Hong Kong.
Subject to a federal tax rate			21%
Income tax rate percentage			30%	30%	30%
EIR rate			25%	25%
EIT rate			10%
Income tax rate					12.50%
Enterprise income tax percentage	25%
Enterprise income tax description			SMEs are entitled to a reduced EIT rate of a reduced EIT rate of 20%, 87.5% reduction of taxable income for the first RMB1,000,000 taxable income and 75% reduction of taxable income between RMB 1,000,000 and RMB 3,000,000, and no reduction for the remaining taxable income for the year ended December 31, 2022; 87.5% reduction of taxable income for the first RMB1,000,000 taxable income and 50% reduction of taxable income between RMB 1,000,000 and RMB 3,000,000, and no reduction for the remaining taxable income for the year ended December 31, 2021; and 75% reduction of taxable income for the first RMB1,000,000 taxable income and 50% reduction of taxable income between RMB 1,000,000 and RMB 3,000,000, and no reduction for the remaining taxable income for the years ended before December 31, 2020.
Research and development expenses percentage		175%
Net operating loss carryforwards (in Dollars)			$ 7,166,560	$ 4,435,381
Net operating loss carryforwards description			The Company also has net operating loss carryforwards from PRC of $5,653,804 which expire starting in 2025 through 2027.
Valuation allowance (in Dollars)			$ 339,495
Corporate taxpayers benefit percentage			50%
Foreign income percentage			10.50%
Hainan Province [Member]
Income Taxes (Details) [Line Items]
EIT rate			15%
Unite States and Hong Kong [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforwards (in Dollars)			$ 1,512,756

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of components of (loss) profit before income tax benefits (expenses) are summarized - USD ($)	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2019
Income Taxes (Details) - Schedule of components of (loss) profit before income tax benefits (expenses) are summarized [Line Items]
Total	$ (2,550,006)	$ (110,753)	$ 4,941,884
PRC [Member]
Income Taxes (Details) - Schedule of components of (loss) profit before income tax benefits (expenses) are summarized [Line Items]
Total	(1,243,361)	631,917	4,976,484
Non-PRC [Member]
Income Taxes (Details) - Schedule of components of (loss) profit before income tax benefits (expenses) are summarized [Line Items]
Total	$ (1,306,645)	$ (742,670)	$ (34,600)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of income tax expenses - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Income Tax Expenses [Abstract]
Current income tax expenses	$ (138,188)	$ (997,198)	$ (543,211)
Deferred income tax benefits	(134,125)	1,346,616	58,424
Income tax benefits (expenses)	$ (272,313)	$ 349,418	$ (484,787)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of reconciliation of statutory tax rate to effective tax rate	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Reconciliation Of Statutory Tax Rate To Effective Tax Rate [Abstract]
PRC statutory income tax rate	25%	25%	25%
Effect of different income tax rates in other jurisdictions	(2.11%)	(34.11%)	0%
Effect of preferential tax benefits	12.72%	167.36%	(13.96%)
Effect of non-deductible expenses	(1.22%)	(54.84%)	0.35%
Effect of research and development credits	3.06%	104.55%	(1.47%)
Effect of deferred tax rate change	(34.22%)	107.53%	0%
Effect of changes in valuation allowance	(13.91%)	0%	0%
Effective tax rate	(10.68%)	315.49%	9.81%

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Excess advertising expense	$ 842,295	$ 911,799
Deferred Intangible assets amortization	25,790	33,590
Net operating loss carrying forward	1,052,209	1,079,962
Share-based compensation	178,764	156,928
Doubtful allowance against accounts receivable	51,817
Changes in fair value of short-term investments	50,502
Downward adjustments in investments in an equity security	13,733
Lease liabilities	71,024	31,615
Less: Deferred tax liability - Right of use assets	(81,910)	(37,184)
Less: Valuation allowance on deferred tax assets	(339,495)
Deferred tax assets, net	1,864,729	2,176,710
Deferred tax liability
Software acquired in business combination	208,200
Deferred tax liability	$ 208,200

(Loss) Earnings Per Share (Deta

(Loss) Earnings Per Share (Details)	Aug. 14, 2019 shares
Class A Ordinary Share [Member]
(Loss) Earnings Per Share (Details) [Line Items]
Stock issued	1,350,068

(Loss) Earnings Per Share (De_2

(Loss) Earnings Per Share (Details) - Schedule of basic and diluted loss per ordinary share - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Basic And Diluted Loss Per Ordinary Share [Abstract]
Net (Loss) Income Attributable to Zhongchao Inc.’s shareholders	$ (2,940,891)	$ 238,665	$ 4,458,380
Weighted average number of ordinary share outstanding
Weighted average number of ordinary share outstanding, basic	25,997,757	24,938,513	24,425,637
(Loss) Earnings per share
(Loss) Earnings per share, basic	$ (0.113)	$ 0.01	$ 0.183

(Loss) Earnings Per Share (De_3

(Loss) Earnings Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Basic And Diluted Loss Per Ordinary Share [Abstract]
Weighted average number of ordinary share outstanding, diluted	25,997,757	24,938,513	24,425,637
(Loss) Earnings per share, diluted	$ (0.113)	$ 0.010	$ 0.183

Related Party Transactions an_3

Related Party Transactions and Balances (Details)	1 Months Ended	12 Months Ended
	Aug. 17, 2022 USD ($)	Dec. 31, 2022 USD ($)
Related Party Transactions and Balances (Details) [Line Items]
Prepaid		$ 118,888
Company balance		$ 144,986
Former shareholders		4
Shanghai Zhongxin [Member]
Related Party Transactions and Balances (Details) [Line Items]
Equity interest		6.67%
Beijing Yisuizhen [Member]
Related Party Transactions and Balances (Details) [Line Items]
Equity interest percentage	47%
Beijing Yisuizhen [Member]
Related Party Transactions and Balances (Details) [Line Items]
Related party transaction balance	$ 392,305
Mr. Yang Weiguang [Member]
Related Party Transactions and Balances (Details) [Line Items]
Company balance		$ 226,178
Mr.Yang [Member]
Related Party Transactions and Balances (Details) [Line Items]
Company balance		$ 81,192

Related Party Transactions an_4

Related Party Transactions and Balances (Details) - Schedule of relationships with related parties	12 Months Ended
	Dec. 31, 2022
Yang Weiguang [Member]
Related Party Transactions and Balances (Details) - Schedule of relationships with related parties [Line Items]
Name	Yang Weiguang
Relationship with the Company	Chairman of the Board, Chief Executive Officer
Beijing Ougaini Trading Co., Ltd (“Beijing Ougaini”) [Member]
Related Party Transactions and Balances (Details) - Schedule of relationships with related parties [Line Items]
Name	Beijing Ougaini Trading Co., Ltd (“Beijing Ougaini”)
Relationship with the Company	Controlled by an immediate family member of Mr. Yang Weiguang
Beijing Yisuizhen [Member]
Related Party Transactions and Balances (Details) - Schedule of relationships with related parties [Line Items]
Name	Beijing Yisuizhen
Relationship with the Company	The Company owned 47% and 100% equity interest before and after August 17, 2022, respectively

Related Party Transactions an_5

Related Party Transactions and Balances (Details) - Schedule of purchase from a related party - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Purchase From ARelated Party [Abstract]
Beijing Ougaini	$ 19,696

Related Party Transactions an_6

Related Party Transactions and Balances (Details) - Schedule of the balances with related parties - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Prepayments
Beijing Ougaini		$ 115,989
Due from related parties
Yang Weiguang	[1]	226,178
Beijing Yisuizhen	[2]		392,305
Total		$ 226,178	$ 392,305
[1]As of December 31, 2022, the Company had a balance of $226,178 due from Mr. Yang Weiguang. The balance was comprised of the following: -A balance of $144,986 arising from transfer of 6.67% equity interest of Shanghai Zhongxin to four former shareholders of West Angel, who paid consideration to Mr. Yang. (Note 4) -A balance of $81,192 as tuition paid on behalf of to Mr. Yang. As of the date of this report, Mr. Yang has repaid the above outstanding balances to the Company.[2]As of December 31, 2021, the Company had a balance of $392,305 due from Beijing Yisuizhen, over which the Company owned 47% equity interest before August 17, 2022. The balance was a loan to the newly set up equity investee to support its working capital. The outstanding balance was repaid by Beijing Yisuizhen before business combination with the Company.

Equity (Details)

Equity (Details) - USD ($)						1 Months Ended	12 Months Ended
	Oct. 10, 2022	Jan. 06, 2022	Sep. 13, 2021	Jul. 13, 2020	Feb. 26, 2020	Dec. 17, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 14, 2019	Apr. 16, 2019
Equity (Details) [Line Items]
Ordinary share authorized (in Shares)							500,000,000
Ordinary share par value (in Dollars per share)							$ 0.0001
Ordinary share stock issued (in Shares)							1,350,068
Ordinary shares, description							Holders of Class A Ordinary Shares and Class B Class A Ordinary Shares have the same rights except for voting and conversion rights. In respect of matters requiring a shareholder vote, each Class A Ordinary Share will be entitled to 1 vote and each Class B Ordinary Share will be entitled to 15 votes.
Percentage of shares issued to shareholders							6.25%
Economic beneficial interest rate							5.19%
Ownership interest rate							1.31%
After-tax profits percentage							10%
Reserve funds percentage							50%
Accrued statutory reserve							$ 115,963	$ 397,552	$ 385,689
Percentage of retained earnings							10%	10%	10%
Statutory reserve funds							$ 1,315,017	$ 1,199,054
Net assets							$ 13,314,132	$ 13,198,169
Tax rate							10%
IPO [Member]
Equity (Details) [Line Items]
Gross proceeds					$ 13,260,000
Class A Ordinary Shares [Member]
Equity (Details) [Line Items]
Ordinary share authorized (in Shares)							450,000,000	450,000,000
Ordinary share par value (in Dollars per share)							$ 0.0001	$ 0.0001
Ordinary share stock issued (in Shares)							1,350,068			14,752,352
Gross proceeds		$ 1,908,000
Aggregate offering price						$ 10,400,000
Sale of ordinary shares (in Shares)		1,060,000
Offering price per share (in Dollars per share)		$ 1.8
Aggregation shares (in Shares)	18,000		18,000	18,000
Class A Ordinary Shares [Member] | IPO [Member]
Equity (Details) [Line Items]
Ordinary share par value (in Dollars per share)					$ 0.0001
Ordinary share stock issued (in Shares)					3,000,000
Per share (in Dollars per share)					$ 4
Class A Ordinary Shares [Member] | Over-Allotment Option [Member]
Equity (Details) [Line Items]
Per share (in Dollars per share)					$ 4
Purchase of additional shares (in Shares)					315,000
Class B Ordinary Share [Member]
Equity (Details) [Line Items]
Ordinary share authorized (in Shares)							50,000,000	50,000,000
Ordinary share par value (in Dollars per share)							$ 0.0001	$ 0.0001
Ordinary share stock issued (in Shares)										5,497,715	10,000
VIE [Member]
Equity (Details) [Line Items]
Statutory reserve funds							$ 1,315,017	$ 1,199,054
Retained earnings
Restricted net assets							$ 13,314,132	$ 13,198,169
Hong Kong [Member]
Equity (Details) [Line Items]
Tax rate							5%

Concentration Risk (Details)

Concentration Risk (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Concentration Risk (Details) [Line Items]
Cost of revenue percentage			10%
Revenue [Member] | Customer A [Member]
Concentration Risk (Details) [Line Items]
Cost of revenue percentage	15.90%	23.40%	26.90%
Revenue [Member] | Customer B [Member]
Concentration Risk (Details) [Line Items]
Cost of revenue percentage		21.90%	19.70%
Revenue [Member] | Customer C [Member]
Concentration Risk (Details) [Line Items]
Cost of revenue percentage		10.70%
Customer A [Member]
Concentration Risk (Details) [Line Items]
Concentration risk percentage	16.60%	20.30%
Customer B [Member]
Concentration Risk (Details) [Line Items]
Concentration risk percentage	0.60%	12%
Customer C [Member]
Concentration Risk (Details) [Line Items]
Concentration risk percentage		11.20%
Customer D [Member]
Concentration Risk (Details) [Line Items]
Concentration risk percentage		10.80%
Supplier One [Member] | Revenue [Member]
Concentration Risk (Details) [Line Items]
Cost of revenue percentage	22.90%	16.40%
Supplier Two [Member] | Revenue [Member]
Concentration Risk (Details) [Line Items]
Cost of revenue percentage		10.20%

Share Based Compensation (Detai

Share Based Compensation (Details) - USD ($)			1 Months Ended	12 Months Ended
	Oct. 10, 2022	Sep. 13, 2021	May 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Restricted shares vested (in Shares)			119,880	15,000	15,000
Restricted shares issued (in Shares)	18,000	18,000
Grant date value of restricted share units (in Dollars per share)	$ 1.16	$ 1.64
Fair value of restricted shares	$ 20,880	$ 29,520
Share-based compensation expenses				$ 160,777	$ 211,832	$ 168,350
share-based compensation expenses incurred				$ 363,670
Weighted average period				3 years 10 months 24 days

Share Based Compensation (Det_2

Share Based Compensation (Details) - Schedule of unvested restricted share units - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Unvested Restricted Share Units [Abstract]
Number of shares, Beginning balance, Unvested	427,076	427,076
Weighted Average Grant-Date Fair Value, beginning balance , unvested	$ 2.53	$ 2.54
Number of shares, Granted	18,000	18,000
Weighted Average Grant-Date Fair Value, Granted	$ 1.16	$ 1.64
Number of shares, Vested	(137,880)	(18,000)
Weighted Average Grant-Date Fair Value, Vested	$ 2.37	$ 1.77
Number of shares, Ending balance, Unvested	307,196	427,076
Weighted Average Grant-Date Fair Value, ending balance , unvested	$ 2.52	$ 2.53

Share Based Compensation (Det_3

Share Based Compensation (Details) - Schedule of share based compensation operating expenses - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Share Based Compensation Operating Expenses [Abstract]
Selling and marketing expenses	$ 61,607	$ 111,997	$ 93,439
General and administrative expenses	99,170	99,826	74,911
Total share-based compensation expenses	$ 160,777	$ 211,823	$ 168,350

Segment Reporting (Details)

Segment Reporting (Details) - segment	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting [Abstract]
Number of Operating Segments	2
Number of Reportable Segments		1

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of presents major accounts of statements of operations	12 Months Ended
	Dec. 31, 2022 USD ($)
MDMOOC Services [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	$ 12,935,420
Cost of revenues	(7,166,871)
Total operating expenses	(9,153,373)
Net Loss	(2,409,212)
Sales of patented drugs [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	1,216,096
Cost of revenues	(627,981)
Total operating expenses	(157,753)
Net Loss	(413,107)
Total [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	14,151,516
Cost of revenues	(7,794,852)
Total operating expenses	(9,311,126)
Net Loss	$ (2,822,319)

Segment Reporting (Details) -_2

Segment Reporting (Details) - Schedule of geographical segments - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total assets
MDMOOC services	$ 37,183,491	$ 36,267,420
Sales of patented drugs	1,430,854
Total	$ 38,614,345	$ 36,267,420

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted average remaining lease term	1 year 9 months 25 days	1 year 4 months 17 days
Operating leases discount rates	4.75%	4.75%
Rental expense	$ 498,166	$ 426,152	$ 312,675
Lease liabilities	$ 409,595	$ 480,636	$ 350,934

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of operating lease related assets and liabilities - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Operating Lease Related Assets And Liabilities [Abstract]
Rights of use lease assets	$ 1,666,777	$ 205,824
Operating lease liabilities, current	480,633	88,968
Operating lease liabilities, noncurrent	1,221,845	112,591
Total operating lease liabilities	$ 1,702,478	$ 201,559

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of maturities of lease liabilities	Dec. 31, 2022 USD ($)
Schedule of Maturities Of Lease Liabilities [Abstract]
2023	$ 550,915
2024	324,647
2025	317,927
2026	317,980
2027 and thereafter	397,475
Total lease payments	1,908,944
Less: imputed interest	(206,466)
Present value of lease liabilities	$ 1,702,478

Condensed financial informati_3

Condensed financial information of the parent company (Details) - Schedule of parent company balance sheet - Parent Company [Member] - Parent Company [Member] - USD ($)	Dec. 31, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 4,110,216	$ 3,758,618
Due from subsidiaries	9,423,617	7,785,162
Investment in subsidiaries, VIE and VIE’s subsidiaries	16,906,213	21,022,642
Total Assets	30,440,046	32,566,422
LIABILITIES AND EQUITY
Total Liabilities
Commitments and Contingencies
Shareholders’ Equity
Class A Ordinary Share (par value $0.0001 per share, 450,000,000 shares authorized; 20,531,423 and 19,453,423 shares issued and outstanding at December 31, 2022 and 2021, respectively)	2,054	1,946
Class B Ordinary Share (par value $0.0001 per share, 50,000,000 shares authorized; 5,497,715 and 5,497,715 shares issued and outstanding at December 31, 2022 and 2021, respectively)	550	550
Additional paid-in capital	24,998,388	22,986,975
Retained earnings	5,439,054	8,379,945
Accumulated comprehensive income		1,197,006
Total Shareholders’ Equity	30,440,046	32,566,422
Total Liabilities and Shareholders’ Equity	$ 30,440,046	$ 32,566,422

Condensed financial informati_4

Condensed financial information of the parent company (Details) - Schedule of parent company balance sheet (Parentheticals) - Parent Company [Member] - Parent Company [Member] - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Class A Ordinary Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Ordinary share par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary share authorized	450,000,000	450,000,000
Ordinary share issued	20,531,423	19,453,423
Ordinary share outstanding	20,531,423	19,453,423
Class B Ordinary Shares [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Ordinary share par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary share authorized	50,000,000	50,000,000
Ordinary share issued	5,497,715	5,497,715
Ordinary share outstanding	5,497,715	5,497,715

Condensed financial informati_5

Condensed financial information of the parent company (Details) - Schedule of parent company statements of operations and comprehensive (loss) Income - Parent Company [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Income Statements, Captions [Line Items]
Equity in (loss) gain of subsidiaries	$ (2,919,423)	$ 266,775	$ 4,470,613
General and administrative expenses	(23,193)	(32,273)	(12,233)
Interest income	1,725	4,163
Net (Loss) Income	$ (2,940,891)	$ 238,665	$ 4,458,380

Condensed financial informati_6

Condensed financial information of the parent company (Details) - Schedule of parent company statements of cash flows - Parent Company [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net Cash Provided by (Used in) Operating Activities	$ 139,309	$ 3,737	$ (700,873)
Cash Flows from Investing Activities:
Loans repaid from (made to) VIE and its subsidiaries	(1,638,455)	(3,400,000)	(3,690,000)
Net Cash Used in Investing Activities	(1,638,455)	(3,400,000)	(3,690,000)
Cash Flows from Financing Activities:
Proceeds from issuance of common stocks in connection with initial public offering, net off issuance cost			11,497,654
Proceeds from issuance of common stocks in connection with direct offering, net off issuance cost	1,850,744
Net Cash Provided by Financing Activities	1,850,744		11,497,654
Net increase (decrease) in cash and cash equivalents	351,598	(3,396,263)	7,106,781
Cash and cash equivalents at beginning of year	3,758,618	7,154,881	48,100
Cash and cash equivalents at end of year	$ 4,110,216	$ 3,758,618	$ 7,154,881